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1.1 Introduction 
Analytical chemistry allows us to study and understand biological systems and diseases 
by exploring the chemistry and behavior of endogenous and exogenous molecules in a 
system. Analytical chemistry is defined by IUPAC as a scientific discipline that develops 
and applies methods, instruments, and strategies to obtain information on the 
composition and nature of matter in space and time1. In other words, disease-specific 
molecules can be revealed, identified, and quantified in a complex system by applying 
the right analytical tools. Clinical validation is required to prove the analytical 
performance of a quantitative method prior to a routine application of analytical 
methods. Validation parameters that are evaluated and established are sensitivity 
(expressed as the concentration measured at limit of detection), precision (expressed as 
standard deviation), accuracy (expressed as percentage-wise error from the exact value), 
and linearity (expressed as correlation coefficient)2. An acceptable outcome of a 
validation study, e.g. meeting predefined validation criteria, can be achieved by 
sufficient instrumental separation power, which is expressed by peak resolution and 
resolving power between two identical peaks.  
 
Mass spectrometry (MS) is a technology that is used for chemical identification, 
localization, and quantification of molecules3. MS has been, often in combination with 
chromatography, revolutionizing the field of analytical chemistry. This chapter 
introduces the fundamentals of mass spectrometry, mass spectrometry imaging (MSI) 
and its application of small molecules. This thesis investigates the hurdles in quantitative 
MSI, as briefly outlined at the end of this introduction. 
 
1.2 Mass Spectrometry 
MS is a unique weighing scale which can measure a variety of molecules, from large 
intact biomolecules to single atoms and isotopes4. Since the first mass spectrum was 
recorded by Sir J. J. Thomson in 1912, developments in the field of MS have led to an 
analytical tool that is currently one of the most sensitive and fastest analytical tools 
available. A mass spectrometer consists of three main building blocks: an ionization 
source, one or more mass analyzers, and an ion detector. In the ionization source, 
molecules are converted into gas-phase ions. A mass analyzer separates the ions based 
on their mass-to-charge (m/z) ratio. If multiple mass analyzers are present in the mass 
spectrometer, a fragmentation cell is present between the mass analyzers to fragment 
selected ions from the previous mass analyzer and separate the obtained fragments in 
the next mass analyzer. The ion detector detects ions from the last mass analyzer, 
measures their abundance, and converts the ions into electrical signals5.  
11
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In mass spectrometry, the mass of a molecule is described in dalton (Da) and defined 
by the sum of the mass of the predominant isotope of all atoms present in the molecule 
(e.g. the exact mass/theoretical mass). When this value is rounded to its integer value, 
it is referred to as the nominal mass of the molecule. A mass spectrum shows multiple 
m/z peaks derived from one ion. The highest abundant peak (e.g. the monoisotopic 
peak) refers to the ion directly related to the molecular weight, either being a radical 
cation, a (de)pronated molecule, an adduct – or fragment-ion, all with the predominant 
isotopes and is followed by m/z peaks that refer to heavier isotopes of this molecule 
which differ one Da from each other. Since a mass spectrum shows m/z ratios, the 
difference between the monoisotopic peak and heavier isotopic peaks can reveal the 
amount of charges present in the ion. 
 
1.2.1 Ionization 
In the ionization process, a neutral molecule either loses or retrieves an electron which 
results in a positive or negative charged version of the molecule, called an ion. A variety 
of ionization techniques are available for the analysis of different classes of molecules 
contained in different sample types. For the right choice of ionization, three factors play 
an important role: i) the sample nature, ii) the molecular structure of the analyte, and 
iii) the transfer of internal energy during the ionization process can cause extensive 
fragmentation of the molecules. In biomolecular MS, two different ionization 
techniques are most frequently used: electrospray ionization (ESI) and matrix-assisted 
laser desorption ionization (MALDI).  
 
Matrix-assisted laser desorption ionization 
Matrix-assisted laser desorption ionization (MALDI) was introduced by Karas and 
Hillenkamp in 1988 and allows the production of intact gas-phase ions6. MALDI 
produces those ions in a two-step process. First, the analytes are dissolved in a solution 
that contains small organic molecules, which is called the matrix. This solution is 
deposited onto a target plate and all solvent is air-dried. This results in analyte-doped 
matrix crystals in which all analytes are surrounded by matrix crystals and completely 
isolated from each other. In the second step, the target plate is placed in the source 
under vacuum conditions. A laser is used to irradiate the matrix crystals which are co-
crystalized with the analyte molecules. The excitation of the matrix molecules by the 
laser causes accumulation of large amounts of energy and results in local sublimation 
of the matrix crystals, expansion of the matrix into the gas plume and charge transfer 
of the matrix to the analyte. Exact details of this mechanism are still not fully 
understood. The most accepted explanation of the physical ionization process are 
12
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excited state proton transfer in the solid phase before desorption and gas-phase proton 
transfer in the gas plume after photoionization of the matrix molecules.7 The basic 
MALDI principle is visualized in Figure 1.1. 
 
 
Figure 1.1 Matrix-assisted laser desorption ionization mechanism (adapted from de Hoffmann et al.4) 
 
The MALDI matrix minimizes damage from the laser by absorbing the energy and makes 
the energy transfer from laser to analyte more efficient. This leads to higher sensitivity 
compared to other laser ionization techniques. Because the MALDI process is driven by 
the energy absorption of the matrix, it can ionize molecules with very large molecular 
weights. MALDI produces predominantly singly charged ions in a pulsed way. Therefore, 
a MALDI source is often combined with a time-of-flight (TOF) mass analyzer due to its 
high mass range and its ability to handle bundles of ions. In addition, MALDI matrix can 
be applied directly on tissue and is a successful technique to study a molecule’s 




Shortly after the development of MALDI in 1988, Fenn et al. revolutionized the mass 
spectrometry field in 1989 by the development of electrospray ionization (ESI)8. Multiply 
charged ions were obtained from proteins and peptides, which allows the detection of 
proteins and peptides with MS instruments that have a limited mass range. Other 
advantages are the very efficient ionization of molecules, its production at atmospheric 
conditions, and the easy incorporation with liquid-based separation techniques, such as 
liquid chromatography and capillary electrophoresis.  
13
General Introduction
147100 Lamont BNW.indd   13 21-12-2020   13:02
 
ESI produces ions by the application of a strong electric field to a liquid passing through 
a capillary tube at a potential difference of 1-5 kV between the capillary and the inlet 
cone. At a low flow rate, gas flows coaxially to prevent dispersion of the spray, which 
then passes through a curtain of heated inert gas (often nitrogen) to help remove the 
last solvent in the droplets. The electric field causes a charge accumulation at the liquid 
surface at the end of the capillary leading to highly charged droplets. When the surface 
tension is broken, the highly charged droplets change into a ‘Taylor cone’ and ESI is 
initiated. Depending on the surface tension of the chosen solvent, the optimal spray 
potential varies. After the formation of the ‘Taylor cone’, the droplet elongates under 
the accumulative force of charge. The solvent in the droplets evaporates and Coulombic 
explosion results in smaller charged droplets. Solvent evaporation will continue until the 
charge on the droplet surface is large enough. In the final ionization step, two major 
mechanisms exist: the ion evaporation model (IEM) and the charge residue model 
(CRM). CRM, where solvent evaporation occurs until one multiply charged ion is 
formed, is the dominant model for the formation of large multiply charged ions. In IEM, 
the dominant model for small molecules, ions are desorbed from the small droplet due 
to the strong electric field in the ion source4, 8, 9. The ESI mechanism is schematically depicted 
in Figure 1.2. 
 
 
Figure 1.2 Electrospray ionization mechanism (adapted from de Hoffmann et al.4) 
 
Because desorption of ions takes place at the surface of the droplet, higher sensitivity 
is achieved for more lipophilic molecules. Molecules that are present in the center of 
the droplet can sometimes be masked by those lipophilic molecules at the surface. 
Larger molecules, such as proteins, will not desorb at the surface but are freed after 
evaporation of the solvent. As mentioned earlier, ESI produces multiply charged ions 
from molecules if they contain multiple ionizable sites in there molecular structure. 
14
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These multiply charged species are recognized in the mass spectrum because their 
isotopic peaks differ <1 Da.   
 
1.2.2 Mass analyzers 
The performance of a mass analyzer is often expressed in terms of speed, sensitivity, 
mass accuracy, mass range, dynamic range, mass resolution, and mass resolving power. 
The speed of a mass analyzer is the rate at which it measures over a particular mass 
range. Sensitivity expresses the efficiency of ion transmission and detection. Mass 
accuracy refers to the error between the theoretical m/z value and the measured m/z 
of an ion. Mass range is the m/z range limit over which the analyzer can measure ions. 
Dynamic range expresses the ratio between the largest and smallest detectable signal. 
Mass resolution is the ability to separate two ions with a small m/z difference. This m/z 
difference is determined between two ions of the same height, which is rarely the case 
in a recorded mass spectrum. Therefore, mass resolving power is the preferred term to 
use with regards to its separation power. Mass resolving power is expressed by the 
observed m/z value divided by the peak width at half height. The greater the mass 
resolving power, the improved capacity to separate ions with a smaller m/z difference. 
The terms mass resolution and mass resolving power are confusingly used in literature, 
however, in this thesis, we prefer to use mass resolving power to express the mass 
analyzer’s separation power.  
 
All mass analyzers separate ions under high vacuum conditions to prevent ions to collide 
and possibly lose their charge. The majority of MS instruments contain one or more of 
the following mass analyzers: Quadrupole10, Linear ion trap11, Time-of-flight12, 
Orbitrap13, and Fourier Transform Ion Cyclotron Resonance (FT-ICR)14. In this 
introduction, we will focus on the mass analyzers used in this thesis.  
 
Quadrupole mass analyzer 
A quadrupole mass analyzer consists of four parallel circular or hyperbolic rods. 
Opposite rods have either a positive or a negative direct current (DC) potential applied 
at which an alternating current (AC) is superimposed. This AC is in the radio frequency 
(RF) region. In simple words, this means that if a positive ion enters the quadrupole 
along the z axis, it is drawn towards a negative rod. Collision of the ion with the rod 
will neutralize the ion and terminates its detection. When the potential changes before 
the ion hits the rod, the ion will change its trajectory. A quadrupole mass analyzer is 
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Figure 1.3 Quadrupole mass analyzer (adapted from Niessen et al.3) 
 
The RF/DC ratio determines which ions have a stable trajectory through the quadrupole. 
The ion trajectory is described by the Mathieu equation (see Equation 1)10: 
 

    2 cos 2ξ  0                     (1) 
  stands for the  and  axis coordinates, ξ is ωt/2, t is time,  is the electron charge, 
 is the DC voltage,  is the RF voltage,  is the mass of the ion,  is the radius 
between the rods, and ω is the RF frequency. The parameters  and  are 
proportional to  and , respectively. To simplify this equation, it is important to 
recognize the relationship between the coordinates of the ion and time. As long as the 
coordinates of the ion are less than  , the ion will not hit the rod and be able to pass 
through the quadrupole. Each quadrupole instrument has a constant  and ω which 
means that for an ion with mass ,  and y can be determined as a function of  and 
 over a certain period of time. This is presented in a Mathieu stability diagram as shown 
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Figure 1.4 Mathieu stability diagram (Figure taken from Kero et al.10)  
 
A quadrupole is often used in three different modes. The first mode is the full scan 
mode in which the RF/DC ratio is fixed while it scans over a certain mass range. This 
mode provides a mass spectrum that contains nominal m/z values. In the second ‘RF 
only’ mode,  = 0 which allows the transmission of all ions through. This way the 
quadrupole is used to focus the ion bundle. In the last mode, which is called selected 
ion monitoring (SIM), only one ion is selected for transmission to the detector by 
keeping the DC/RF values at a fixed value. Sequential selection of multiple ions is 
possible with the switching time is often  ̴5 ms.  
 
Time-of-flight mass analyzer 
In a linear time-of-flight (TOF) mass analyzer, ions are initially accelerated by an electric 
field in a pulsed manner followed by a separation based on individual velocities as they 
drift through the field-free region4, 15. When an ion with mass  and charge  is 
accelerated by a potential , this energy is converted into the kinetic energy of the ion. 
The velocity  is determined by the following equations (Equation 2 and 3):   
 
                 (2) 
 
The flight time  and m/z value are then calculated by considering the velocity of the 
ion and the flight tube distance : 
 
        (3) 
17
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Most TOF instruments contain a reflectron to improve its mass resolving power. The 
reflectron, which consists of a set of serial grids situated behind the field-free region, 
acts as an ion mirror by sending the ions back through the flight tube. Faster ions, with 
more kinetic energy and more velocity, will penetrate the reflectron deeper than slower 
ions of the same m/z. Due to the reflectron, the total flight distance is prolonged and, 
additionally, the kinetic energy dispersion of ions with the same m/z is corrected for (in 
other words ‘time-focused’). Both of these features are leading to higher mass resolving 




Figure 1.5 Time of flight mass analyzer (adapted from Mamyrin et al.12) 
 
Trapped ion mass analyzers 
This section briefly explains two trapped ion mass analyzers: a linear ion trap (LIT) and 
an orbitrap mass analyzer. The mechanism of a LIT is similar to that of the quadrupole 
mass analyzer11. In a LIT, the four parallel rods have lenses on both ends to repel ions 
inside the rods, either at positive (for positive ions) or negative (for negative ions) 
potential. Ions are cooled by collisions with an inert gas (N2) moving along the z-axis 
along the rods while oscillating in the xy-plane. In addition to the end lenses, the four 
rods are divided into three segments: two segments at the end have a DC voltage 
applied to repel ions while the middle segment is kept at RF-only potential. Ions are 
ejected from the LIT by applying additional AC voltages between the rods and the end 
electrode (the exit lens). 
 
The orbitrap mass analyzer was introduced by Makarov et al. in 2000 and is an 
electrostatic ion trap that uses Fourier transform to generate mass spectra13. It consists 
of an internal (spindle-shaped) and external (barrel-shaped that is cut into two equal 
parts) electrodes. Ions are injected into the trap via this opening in the external 
18
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electrode. The internal electrode has an electrostatic DC voltage of several kilovolts 
applied to (negative for positive ions and vice versa) and the external electrode is at 
ground potential. Ions with several kiloelectronvolts kinetic energy are injected and start 
to rotate around the internal electrode while moving along the z-axis. The frequency of 
oscillations is directly linked to the m/z ratio and is independent of the kinetic energy of 
the ions. The broadband current induced by the oscillating ions is converted by a Fourier 
transform to individual frequencies and intensities in the mass spectrum. An extensive 
explanation of the orbitrap mass analyzer can be found in this reference16.  
 
1.2.3 Ion detection 
After separation of the ions based on their m/z value in the mass analyzer the individual 
ions need to be detected. The travelling ions need to be converted into an electric 
current which is, ideally, proportional to their abundance. Because the number of ions 
that leave the mass analyzer is very low, they need to be amplified to obtain a sufficient 
signal. This is often done by an electron multiplier, which consists of multiple conversion 
dynodes (electrodes) at a high potential. The first dynode is of opposite potential than 
the ions of interest. When e.g. positive ions hit the first conversion dynode, secondary 
particles are generated such as negative ions and electrons. Negative ions result in 
positive ions after hitting the first conversion dynode, which are then converted into 
negative ions and electrons. This electron amplification continues until a significant 
number of electrons are generated. These secondary electrons are collected by an 
anode at the end of the detector and the current is measured. In some instruments a 
photomultiplier is used for ion detection, which transfers the secondary electrons into 
photons by accelerating them towards phosphorescent screen. A photomultiplier 
detects these photons and converts them into an electric current. The main advantage 
of a photomultiplier over an electron multiplier is its lifetime and fast response time. In 
addition, for fast data acquisition in MS, fast electronics such as analog-to-digital 
converters (ADCs) are necessary. An ADC receives ion arrival times and number of ions 
(ion intensity) and converts this information into a digital output to generate a mass 
spectrum. Detection in an FT-ICR or orbitrap is more complicated and will not be 
discussed in this introduction. More information can be found in the following 
references13, 14, 17, 18. 
 
1.2.4 Tandem mass spectrometry 
MS not only allows the detection of molecules in a complex mixture but can also be 
used to identify them. Structural identification of molecules requires fragmentation of 
their ions which can be done by tandem mass spectrometry (MS/MS)3, 4, 19. In a tandem 
19
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mass spectrometer, two or more mass analyzers are present with a fragmentation cell 
in between. MS/MS can be distinguished into two types: in space and in time20. MS/MS 
in space occurs in an instrument that contains two mass analyzers. Identification is 
performed by using the first mass analyzer to select the ion of interest (e.g. precursor 
ion), fragment this ion into structurally identifiable fragment ions (e.g. product ions), 
measure the m/z values of these fragment ions in the second mass analyzer. MS/MS in 
time is performed in an instrument that contains one mass analyzer, often in trapped-
ion mass spectrometers. The precursor ions are selected in the mass analyzer (all other 
ions are eliminated from the trap), collision gas is introduced to generate fragment ions, 
and afterwards fragment ions are measured in the same mass analyzer. This successive 
way of analyzing can be repeated for several times to obtain fragments of fragment 
ions (e.g. MSn). 
 
Although the general principle is the same, different fragmentation methods are 
available which leads to different fragment ions. The fragmentation method used in 
this thesis is called collision-induced dissociation (CID)21, 22. In the fragmentation cell, 
collisions between the precursor ions and an inert collision gas (often N2) cause the 
kinetic energy to be converted into internal energy which brings the ion into an excited 
state leading to decomposition/fragmentation.  
 
MS/MS in space is often executed on two MS instruments: a triple quadrupole mass 
spectrometer (QqQ) and a quadrupole time-of-flight mass spectrometer (Q-TOF). The 
MS/MS capabilities of both instruments are described in more detail below.  
 
Triple quadruple mass spectrometer 
A triple quadrupole (QqQ) instrument consist of two quadrupole mass analyzers (Q1 
and Q3) with a fragmentation cell (q) in between. Historically, the instrument was built 
with three quadrupoles the second of which was used as q. In modern instruments, q 
is replaced by a higher-order multipole, which makes the term triple quadrupole not 
accurate. This instrument is, therefore, often called a tandem quadrupole mass 
spectrometer. However, in this thesis, we refer to this instrument as a triple quadrupole 
in consistency with common practice within the MS community3.  
 
As described previously in this introduction, a quadrupole mass analyzer can be used in 
three operational modes. When two mass analyzers are placed in one MS instrument, 
this allows for four different QqQ MS/MS modes presented in figure 1.6: i) product ion 
scan (PROD), ii) precursor ion scan (PREC), iii) neutral loss scan (NL), and iv) selected 
reaction monitoring (SRM)23, 24. In PROD, a precursor ion is selected in Q1, fragmented 
in q, and fragment ions are scanned in Q3. In PREC, the precursor ions that contain one 
20
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specific fragment ion (selected in Q3) are scanned in Q1. In NL, precursor ions in Q1 
and fragment ions in Q3 are scanned with an offset corresponding to a neutral 
fragment loss from the precursor ions. In SRM, Q1 and Q3 are both used in SIM mode, 
which results in a specific precursor ion-fragment ion transition. This way all other ions 
are removed and focus on this transition can be held for a longer period of time which 
leads to a significant boost in sensitivity. SRM is often applied on multiple transitions 
and is, therefore, referred to as multiple reaction monitoring (MRM). In MRM, one 
should be aware of the cross-talk between multiple MRM transitions with the same 
fragment ions. Multiple transitions from the same precursor ion can confirm its 
identification. Fast switching times between MRM transitions allows for sensitive high 
throughput screening of large amounts of molecules. In addition, a QqQ instrument 
offers a high dynamic range which makes it very suitable for molecular quantification.  
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Quadrupole time-of-flight mass spectrometer  
A quadrupole is combined with a reflectron TOF analyzer in a Q-TOF instrument 
separated by a fragmentation cell to perform MS/MS with high mass resolving power 
26. In full scan mode, both the quadrupole and fragmentation cell are used in RF only 
mode. In MS/MS mode, the quadrupole is used for precursor ion selection and the TOF 
is, after fragmentation, used for high mass resolving power scanning of fragment ions. 
Because a TOF analyzer is a pulsed system that requires ions to be introduced in bundles, 
the combination with a continuous ion beam from ESI requires orthogonal acceleration 
in the instrumental setup27. Orthogonal acceleration transforms a continuous ion beam 
into a pulsed process by applying an electric field in the orthogonal direction of the ion 
beam and accelerates the ions into the TOF analyzer. Because of this high mass 
revolving power scanning, a Q-TOF instrument is a very suitable instrument for 
structural identification of unknown molecules. 
 
1.3 Structural analysis 
MS/MS is necessary to determine the molecular structure of an unknown compound28-
30. Hsu and Turk have shown structural characterization for multiple lipid classes by 
direct infusion combined with MS/MS31-39. Even though the information provided by 
MS/MS is essential, some lipid isomers are still challenging to identify. In general, 
isomers are different molecules with the same chemical formula and, therefore, the 
same exact mass40. In some unknown cases, even fragments from isomers are identical 
and could not be separated by MS. The term isomers should not be confused with 
isobars, which refers to two molecules with the same nominal mass but not the same 
molecular formula, thus different exact mass. Isobars could be isolated using MS with 
high enough mass resolving power while MS alone cannot isolate isomers. In that 
perspective, isomers can be divided into two groups: structural isomers (same molecular 
formula, different atom sequence) and stereoisomers (same molecular formula and 
atom sequence, different 3D orientation of atoms)40. Structural isomers can often be 
separated by MS/MS but stereoisomers are not. These molecules require 
complementary separation to MS/MS to perform structural analysis, such as nuclear 
magnetic resonance (NMR) spectroscopy41. This is quite challenging because NMR 
requires a much more concentrated/pure sample and is very time-consuming. In 
addition to resolving stereoisomers by NMR, biological samples are very complex and 
their mass spectra show isobaric interference due to this complexity. Therefore, they 
require cleanup/concentration before NMR/MS identification, which can be achieved by 
complementary separation prior to NMR/MS analysis. The complementary separation 
tools that frequently used are gas chromatography (GC)42, 43. liquid chromatography 
(LC)44-46, capillary zone electrophoresis (CZE)47-49, and ion mobility spectrometry (IMS)50-
22
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54. These techniques simplify a mass spectrum and, as a result, may lead to structural 
identification. In this thesis, two separation techniques are further explained: IMS and 
LC. 
 
1.3.1 Ion mobility spectrometry  
Ion mobility spectrometry (IMS) separates gas-phase ions based on their size-to-charge 
ratio as they are moving through a buffer gas by an applied electric field55-57. The ion’s 
velocity  is expressed by the multiplication of its mobility  and the electric field  
(Equation 4):  
 
      (4) 
 
Under low field conditions, the ion mobility constant  is related to the collision cross-
section Ω of the ion by the Mason-Schamp equation (Equation 5)58, 59: 
 
    /  /   (5) 
 
in which  is the ion’s charge,  is the number density of the buffer gas,  is the 
Boltzmann’s constant,  the absolute temperature,  is the mass of the buffer gas and 
 is the mass of the ion. 
IMS is combined with MS since the 1960s. Four different IMS techniques are 
distinguished: i) drift tube ion mobility spectrometry (DTIMS)60, ii) travelling wave ion 
mobility spectrometry (TWIMS)58, 61, 62, iii) trapped ion mobility spectrometry (TIMS)63, 64, 
and iv) field asymmetric ion mobility spectrometry (FAIMS)65-68. The basic principles of 
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Figure 1.7 Four main types of ion mobility spectrometry: drift tube ion mobility spectrometry (DTIMS), 
travelling wave ion mobility spectrometry (TWIMS), trapped ion mobility spectrometry (TIMS), and field 
asymmetric ion mobility spectrometry (FAIMS). 
 
DTIMS measures the time an ion moves through a buffer gas while a low electric field 
is applied69. DTIMS can be used under two conditions: atmospheric pressure and 
reduced pressure. Reduced pressure DTIMS has a better ion transmission to the mass 
spectrometer than DTIMS at ambient conditions but loses resolving power versus 
atmospheric pressure DTIMS55. TWIMS is the second IMS type in which ions pass 
through the buffer gas accelerated by symmetric potential waves. Overall, TWIMS offers 
better ion transmission efficiency due to the higher vacuum conditions58. TIMS separates 
ions based on a reversed principle: ions are carried into the IMS cell by a carrier gas and 
trapped by the electric field63, 70. All three described IMS techniques operate at low-to-
moderate electric field conditions, which makes the Mason-Schamp equation applicable 
and the linear  to  relationship classifies them as linear IMS. FAIMS is considered 
nonlinear IMS because separation takes place when applying an asymmetric wave field 
that rapidly applies high and low electric fields. This rapid field switching separates ions 
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while transported between two planar electrodes by a carrier gas65, 71. FAIMS has proven 
to be far more orthogonal to MS than linear IMS techniques72.  
 
1.3.2 Liquid chromatography  
Chromatography covers a group of analytical methods that allow the separation of 
isomeric compounds in complex biological mixtures. The technique is established in 
analytical chemistry as in some cases chromatography is the only applicable tool with 
sufficient separation power. The basic principle is the same for all chromatographic 
separations. A sample is dissolved in a mobile phase, either a gas (GC) or a liquid (LC), 
and passed through a stationary phase73. In LC, the stationary phase is a packed column 
with particles. Because analytes in the sample can only move when they are in the 
mobile phase; they are more or less retained dependent on the time they spend in the 
stationary phase. For sufficient separation power, two analytes should be retained for 
a certain amount of time. However, the more time an analyte spends on a column, the 
broader its peak will be. Chromatographic separation of similar molecules is affected 
by chemical and physical parameters (of the column) that improve peak separation 
while limiting the amount of peak broadening. The performance of a chromatographic 
column, so-called column efficiency, is expressed by two terms: plate height  and 
number of theoretical plates . A theoretical plate is a hypothetical stage at which both 
phases are at equilibrium with each other. The more theoretical plates, the more 
efficient is the column. The two terms are related to each other by the Equation 6 73: 
 
      (6) 
 
in which  is the column length. A low plate height is desirable and should be 
considered during column tests. The Van Deemter plot and equation (Equation 7) 
express the plate height by three terms that represent column processes during the 
chromatographic interaction: eddy diffusion term , longitudinal diffusion term / 
and mass transfer term  ∙ 74-76.  
 
         ∙    (7) 
 
 is the eddy diffusion coefficient,  is the longitudinal diffusion coefficient,  the sum 
of the mass transfer coefficients of both phases and  the linear velocity of the mobile 
phase (cm/s). Eddy diffusion reflects the possibility of a molecule to diffuse in the 
column packing if the mobile phase flow rate is not optimal which leads to peak 
broadening. Longitudinal diffusion is the migration of the sample to more dilute regions 
of the ‘sample zone’ on both sides. At higher flow rates, this term has minimal effect 
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on the plate height. The mass transfer term is defined by two mass transfer coefficients 
for both the mobile () and stationary phase (), which reflect both the travelling time 
through the mobile phase and the time required to be adsorbed to/desorbed from the 
stationary phase. The higher the flow rate, the less migration time for the analyte to 
interact with the stationary phase.  is proportional to the square of the particle 
diameter and column diameter. A narrower column with smaller particles allows for 
more interaction (and therefore retention) with the stationary phase and can facilitate 
higher flow rates. Since the late 1960s, LC systems improved so they could perform at 
higher pressures (from 250 bar up to 1000 bar), referred to as high-performance liquid 
chromatography (HPLC) systems, which were further upgraded to ultra high-
performance liquid chromatography (UHPLC or UPLC) systems in 200477. As UHPLC 
systems became the standard for routine chromatographic analysis, these systems are 
abbreviated as LC in literature. 
 
1.4 Mass spectrometry imaging 
MALDI based Mass spectrometry imaging (MSI) was first reported by Caprioli et al. in 
1997 in which proteins and peptides were imaged in biological tissue by MALDI-TOF78. 
Since its introduction, MSI has grown into an indispensable field for label-free spatial 
MS profiling directly from a surface and is recognized as a valuable tool in 
pharmaceutical79-83, biomedical84-87, and clinical research88-90. MSI is used to study the 
distribution of not only endogenous molecules like proteins and lipids but also 
exogenous compounds such as pharmaceuticals, all on very complex surfaces91-94. These 
molecules can be mapped at the sub-cellular level using an ionization tool that can 
provide high spatial resolution and even larger surfaces like complete organs and whole 
biological systems can be imaged95. In addition to the MS performance characteristics 
discussed previously, important features of an MSI technique are its spatial resolution 
(often expressed in pixel size) and its speed (often expressed in pixels per second). The 
higher spatial resolution is used, the longer analysis time is required to maintain the 
same ion detection level. This is a constant consideration for the application in clinical 
and pharmaceutical research in which fast and high throughput analysis is required. 
The basic MSI workflow (Figure 1.8) consists of four building blocks: spatial ionization, 
MS analysis, single pixel mass analysis, and the construction of m/z specific intensity 
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Figure 1.8 Mass spectrometry imaging workflow. 
 
A variety of MSI ionization techniques is available, such as MALDI96, secondary ion MS 
(SIMS)97, 98, and desorption electrospray ionization (DESI)99, 100. These three MSI 
ionization technique have been groundbreaking for the MSI field and deliver 
complementary characteristics in terms of target analytes, spatial resolution and sample 
preparation. MALDI-MSI is by far the most applied MSI technique since it is applicable 
to many different compound classes. After the matrix application, which is sprayed or 
sublimed over the sample surface, a MALDI laser is used to spatially ionize molecules 
present in the sample. The spectra in the obtained MS images correlate with the X- and 
Y-coordinates of the laser shots101. Spatial resolution in MALDI-MSI is typically around 
20-30 µm, however, a minimal pixel size of >5 µm has been reported102-104. MALDI-MSI 
achieves high sensitivity for a wide range of molecules but its main limitation is the time-
consuming matrix application. The matrix application step can lead to analyte 
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delocalization and suppression of ions due to the matrix crystals105. Research has 
extensively focused on the optimization of sample preparation protocols that involve 
tissue washing106, on-tissue digestion107, 108, on-tissue derivatization109-111, and sublimed 
matrix application in combination with recrystallization112. All studies targeted the 
improvement of molecular discovery or spatial resolution through the improvement of 
sample preparation methodology. 
 
SIMS uses a primary ion beam to generate secondary ions from a surface113. The primary 
ion beam can be focused to a <100 nm spot size and is ideal for sub-cellular imaging. 
SIMS often results in fragmentation of molecules due to the high amount of energy 
from the primary ion beam on a very small surface, which makes detection large 
biomolecules difficult. As a result, SIMS is the preferred MSI tool for imaging small 
molecules and elements when high spatial resolution is required95. Ambient MSI 
techniques, including DESI, are used in the research presented in this thesis and are 
further discussed in more detail.  
 
1.4.1 Ambient mass spectrometry imaging 
Several MSI ionization techniques perform at atmospheric pressure. These ambient 
ionization techniques do not require matrix application and are compatible with 
samples that cannot be placed under vacuum conditions114-116. Ambient MSI ionization 
often uses a solvent to extract molecules of interest from the sample prior to ionization 
or desorb and ionize molecules directly from a substrate. Although lower sensitivity is 
observed for larger biomolecules, the ability to adapt the solvent composition to the 
targeted compound (classes) is a major advantage of ambient MSI100. Common ambient 
MSI ionization techniques are: desorption electrospray ionization (DESI)99, 117, 118, laser 
ablation electrospray ionization (LAESI)119, 120, liquid extraction surface analysis (LESA)121, 
122, which is often referred to as liquid microjunction surface sampling probe (LMJ/SSP; 
flow probe)123-125, nanospray desorption electrospray ionization (nano-DESI)126, 127, and 
laser ablation liquid capture surface analysis (LA/LCSA)128, 129. Laskin et al. provided an 
informative review, which explains multiple ambient MSI techniques130.  
 
Desorption electrospray ionization 
DESI is the most widely applied ambient MSI technique and was first reported in 2004117, 
118. Its mechanism combines ESI and desorption ionization. DESI uses a supersonic 
electrospray jet which is directed to a sample surface. A potential of 1-5 kV is applied 
to generate primary charged solvent droplets that are focused towards the sample by a 
high speed nebulizing gas (e.g. N2). These primary charged droplets form a small thin 
liquid layer on the sample in which extracted molecules are desorbed. Secondary 
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charged droplets are obtained due to the continuous bombardment of the electrospray 
into the thin liquid layer. The solvent in these secondary charged droplets evaporates 
and molecules are ionized. This mechanism is illustrated in Figure 1.9.  
 
 
Figure 1.9 A schematic overview of desorption electrospray ionization. 
 
DESI has several advantages compared to MALDI. First, no matrix application is needed 
which minimizes the sample preparation time. Second, multiply charged ions are 
generated which extends the mass range (similar to ESI). In addition, the DESI solvent 
can be targeted to the analytes of interest. DESI is nondestructive to the tissue sample 
which allows complementary MALDI-MSI analysis afterwards131. As with all ambient 
ionization techniques, DESI does not require vacuum condition. Pixel sizes in DESI are 
often around 50 um with a minimal >20 um reported132. The DESI source can move fast 
and therefore can scan samples with high throughput (< 5 min/analysis) in a clinical 
assessment133, 134.  
 
Liquid extraction surface analysis 
LESA was first described by Kertesz and coworkers in 2010 and uses a liquid droplet to 
extract molecules from a surface prior to direct MS analysis via nanoelectrospray 
ionization135. LESA has similar advantages as other ambient MSI techniques as it requires 
minimal sample preparation and extraction solvent can be modified to the target 
analytes136. However, spatial resolution of LESA is around 1-1.5 mm in which several 
histological features are lost compared to other MSI techniques. For this reason, LESA 
is often applied as a spatial profiling tool. The major advantage of LESA is that this 
spatial extraction unit can be combined with chromatographic separation, such as thin 
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layer chromatography or even column based LC, to provide an additional dimension 
complementary to MS123, 137.  
 
 
Figure 1.10 The principle of liquid extraction surface analysis. 
 
1.5 Pharmaceutical development  
In drug discovery and drug development, the main goal is finding suitable drug 
candidates that can inhibit or activate a pathway or protein to have a positive effect in 
a disease state82. Pharmacology studies various interactions of a drug candidate with a 
biological system by pharmacokinetics (what the system does to the drug; PK) and 
pharmacodynamics (what the drug does to the system; PD)138. In general, the desired 
effect is that the potential drug is distributed, and if required metabolized, to the target 
site and bound to the biological receptors present for a certain amount of time at a 
high enough concentration139, then released and excreted as soon as possible, all 
without initiating a toxic effect. PD investigates the drug binding to the biological 
receptors while PK is monitored by absorption, distribution, metabolism, and excretion 
(ADME) studies. PK and PD are integrated to study the drug dose-drug concentration-
response relationship. In some cases, a drug candidate or its metabolites can 
accumulate in tissue which can result in significant toxicity140. Toxicology studies the 
adverse effects of a potential drug by determining the right dosing route (i.e. oral, 
intravenous (IV), inhalation or dermal) and the dosage (duration/concentration of 
exposure to drug candidate). Therefore, not only PKPD studies but also toxicology 
studies of a drug candidate and/or metabolites play a key role in deciding whether a 
potential drug will get a go or no-go141. Throughout the drug discovery and 
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development, failing ADME studies are the major reason for a no-go. This occurs not 
only in early development stages but also in Phase II and Phase III of clinical trials. 
Compounds that are promising during cell-based assays might not give promising 
results in vivo due to the complex relationships between human bodies, environmental 
factors, or even drug characteristics. ADME and toxicology studies are applied at a much 
earlier stage of the drug discovery and development pipeline to understand and avoid 
these failing potential drug compounds. What is vital in this process is the ability to 
measure the distribution and absolute concentration over time of both the drug and 
corresponding metabolites in tissue samples. 
 
Currently, the measurement of spatial information of pharmaceutical compounds is 
achieved by combining a whole-body autoradiography (WBA) and an MSI strategy on 
tissue samples. WBA combines localization information, with spatial resolutions of 
around 100 µm, and quantification in one experiment, but it cannot distinguish 
between drugs and their metabolites. This methodology uses a radiolabel attached to 
the drug, which is often expensive and time-consuming to prepare, preliminary to 
dosing. Absolute concentrations are obtained by quantitative WBA and LC-MS/MS on 
tissue homogenate samples. Despite the fact that LC-MS/MS platforms offer robust and 
reproducible absolute concentrations, this approach alone is not as it does not provide 
the spatial information of the drug candidate and its metabolites necessary for 
pharmacokinetics and toxicology studies. MSI, WBA and LC-MS/MS are often 
complementarily applied to tissue sections to cover the demand for quantification, 
spatial distribution of drugs, and identifying corresponding metabolites. 
 
MSI has evolved as a valuable qualitative tissue imaging tool in pharmaceutical research. 
Multiple reviews have been written about the role of MSI in the pharmaceutical 
industry80, 83, 141, 142. Table 1.1 provides an extensive overview of drugs and metabolites 
studied qualitatively by MSI which is updated and extended from Swales et al.142. The 
overview provides not only information on the dosing route and concentration but also 
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A large number of drug compounds has been studied by MSI, either existing drug 
compounds or compounds in development. For some of these compounds, metabolites 
were measured in the tissue section. Dosing concentrations were adapted to the weight 
of the animal. In most studies, a single drug compound is exclusively investigated. 
However, a few of the applications explored dosing multiple drug compounds. Swales 
et al. performed two cassette dosing experiments with different existing drug 
compounds: i) haloperidol, bufuralol, midazolam and clozapine and ii) moxifloxacin, 
olanzapine, erlotinib and terfenadine155. Two other applications by Manier et al. and 
Chumbley et al. report MSI analysis of tissues from tuberculosis-infected rabbits which 
were dosed rifampin, isoniazid, pyrazinamide and moxifloxacin168, 190. Tissues analyzed 
in the applications presented in Table 1.1 ranged from one or several organs to whole 
body imaging. The majority of the MSI drug applications has been performed by MALDI 
imaging since it has proven a valuable ionization tool for drug and drug metabolite 
imaging with high spatial resolution. Since the identification of the drug compounds 
imaged is obligatory, either MS/MS or SRM/MRM were used to confirm the compounds 
detected, often in combination with high mass resolving power instrumentation.  
 
1.6 Quantitative MSI 
The demand for quantitative MSI (Q-MSI) has increased significantly over the years and 
is currently one of the main challenges for the MSI community. In particular for the 
pharmaceutical industry, since spatial absolute concentrations while maintaining 
separation between drug candidate and metabolites is key in the development pipeline 
and minimizing costly failing drug candidates. The spatial absolute concentrations are 
used to predict the dose concentration, to perform pharmacokinetic investigations and 
to measure the toxicity thresholds. In MSI, the lack of sample cleanup causes a relatively 
large effect of ion suppression on the analyte caused by the surrounding molecular 
composition. In particular, the heterogeneity in tissue samples increases this ion 
suppression effect and variability throughout the imaging analysis201, 202. Quantification 
in LC-MS/MS often involves the use of internal standards, isotope-labelled analogs of 
the analyte, to normalize for ion suppression. However, the application of these internal 
standards and, therefore, gaining reliable quantitative data in MSI still poses practical 
challenges. Several strategies have been addressed by Ellis et al. and Porta et al. on the 
implementation of internal standards in MSI201, 203. Since the main role of internal 
standard is to undergo similar ion suppression effects as the analyte of interest, the 
importance lies in the extraction of the internal standard by the matrix from the tissue 
sample prior to ionization which is better obtained by applying the internal standard 
below the tissue sample rather than on top of the tissue sample203, 204. Pirman and 
coworkers used a quantitative MALDI-MSI approach to determine cocaine in brain tissue 
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with the use of a deuterated internal standard, as well as the calibration standards, 
below the tissue sample205. The Q-MSI results are compared with the complementary 
LC-MS/MS and MALDI-MS/MS experiments and show the potential of Q-MSI, however, 
due to extrapolation to the x-axis, the quantitative performance of this approach has 
still some hurdles to overcome. In addition to spraying the calibration standards below 
(or on top of) the tissue, tissue homogenates spiked with calibration standards has also 
proven to provide absolute concentrations which is demonstrated by Groseclose et 
al.206. This time consuming but very reliable approach is called a mimetic tissue model 
and has been revised to improve the sample preparation207.  
The use of an isotope-labelled internal standard for absolute quantification is the ideal 
approach but not always available if a drug candidate is in early stage development. 
Since ion suppression on the analyte is not only compound specific but also tissue 
specific, Hamm et al. reported the tissue extinction coefficient (TEC) as a correction 
factor for different tissue types within a whole body208. A known compound is mixed 
with the MALDI matrix and homogeneously sprayed over the whole body prior to MSI 
analysis. The TEC is calculated for each tissue organ by dividing the average intensity of 
the known compound on tissue by the average intensity on the glass slide.  
 
1.7 Scope and outline 
Challenges in quantitative MSI (Q-MSI) of pharmaceutical compounds are often the 
result of limited separation prior to MS analysis. Not only does this lead to low analyte 
coverage due to ion suppression from surrounding sample molecules but also to isobaric 
interferences in the mass spectrum because of the presence of those surrounding 
molecules. The aim of this thesis is to develop and apply enhanced separation 
techniques in the field of ambient Q-MSI. First, novel technological developments are 
presented to minimize ion suppression and add selectivity and sensitivity. This is 
executed by the integration of LC, IMS and MRM in an MSI workflow. After the 
technological development, the right imaging tool is used for the ambient Q-MSI 
analysis of pharmaceuticals.  
 
In chapter 2, we report an LC-MS setup in combination with high resolution spatial 
sampling using LESA. This fully automated platform motivates the use of LC and IMS 
for additional separation to MS. The integration of LC minimizes the inefficient 
ionization by decreasing the amount of surrounding molecules. IMS separates isobaric 
background molecules from the analyte and adds selectivity to the high resolution LESA-
µLC-IMS-MSE platform. This research is complemented with data-independent analysis 
for structural identification of peptides. From an application point-of-view, this research 
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shows improved neuropeptide coverage in the pituitary gland in an Alzheimer’s Disease 
model.  
 
Chapter 3 presents a Girard’s T (GT) derivatization strategy to improve ionization 
efficiency of poorly ionizable prostanoid metabolites. Separation of these biologically 
relevant isomers often requires chromatography prior to ionization and MS. For imaging 
purposes, these GT derivatized prostanoids are used in an IMS comparison for isomeric 
separation: cyclic IMS, TIMS, and high resolution FAIMS. Does the improved IMS 
resolution come with a decrease in sensitivity? To answer this question, their biological 
applicability of these IMS types is shown after an extraction and GT derivatization of 
endogenous prostanoid metabolites from intestine tissue. 
 
Chapter 4 describes targeted MSI which combines DESI ionization with specific MRM 
imaging by using a QqQ instrument. All modes of the QqQ instrument are presented 
for visualization of lipid distributions in brain tissue. High throughput imaging by 
multiple MRM transitions of the same analyte confirms its spatial localization in a second 
application, dog liver tissue from a drug distribution study. Dual polarity MRM analysis 
shows its strength by mapping possible co-localized metabolites and lipids without the 
need for consecutive tissue sections.  
 
The application of DESI-MRM imaging in Q-MSI is reported in chapter 5. This chapter 
starts with the presentation of an adapted mimetic tissue model using a 3D printed 
mold for gelatin embedding. A multiplatform comparison is performed to study the 
analytical performance of different mass spectrometers (each in different modes) in 
relationship to MRM imaging. The latter is used for quantitative analysis of different 
regions of interest in four dog liver tissues from the previous drug distribution study. 
The Q-MSI data is compared with LC-MS concentration obtained from the same dog 
livers.  
 
The technological improvements for ambient Q-MSI that are established in this thesis 
are discussed in Chapter 6: Enhanced analyte coverage, improved isobaric and isomeric 
separation, higher selectivity and sensitivity, and MRM based quantification.  
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Direct analysis by mass spectrometry (imaging) has become increasingly deployed in 
pre-clinical and clinical research due to its rapid an accurate readouts. However, when 
it comes to biomarker discovery or histopathological diagnostics, more sensitive and in-
depth profiling from localized areas is required. We developed a comprehensive, fully 
automated online platform for high-resolution liquid extraction surface analysis (HR-
LESA) followed by micro–liquid chromatography (LC) separation and a data-
independent acquisition strategy for untargeted and low abundant analyte 
identification directly from tissue sections. Applied to tissue sections of rat pituitary, the 
platform demonstrated improved spatial resolution, allowing sample areas as small as 
400 µm to be studied, a major advantage over conventional LESA. The platform 
integrates an on-line buffer exchange and washing step for removal of salts and other 
endogenous contamination that originates from local tissue extraction. Our carry over–
free platform showed high reproducibility, with an inter-extraction variability below 
30%. Another strength of the platform is the additional selectivity provided by a post-
sampling gas-phase ion mobility separation. This allowed distinguishing co-eluted 
isobaric compounds without requiring additional separation time. Furthermore, we 
identified untargeted and low-abundance analytes, including neuropeptides deriving 
from the pro-opiomelanocortin (POMC) precursor protein and localized a specific area 
of the pituitary gland (i.e., adenohypophysis) known to secrete neuropeptides and other 
small metabolites related to development, growth, and metabolism. This platform can 
thus be applied for the in-depth study of small samples of complex tissues with 
histologic features of ~400 µm or more, including potential neuropeptide markers 





147100 Lamont BNW.indd   42 21-12-2020   13:03
2.1 Introduction 
Mass spectrometry imaging (MSI) is being used more often in pre-clinical and clinical 
research due to its many advantages over conventional imaging techniques209-211. MSI 
offers the possibility to correlate distribution maps of multiple molecular species 
simultaneously with histological and clinical features without labelling. This 
methodology enables the discovery of potential diagnostic and prognostic markers of 
diseases in a single experiment. With these unique features, MSI opens new doors for 
molecular-driven pathology, in various fields of histopathological diagnostics, such as 
identification and grading of tumors89, 212. MSI has also proven to be a powerful tool in 
drug discovery as it gives insights not only on drug and metabolite distribution and 
site(s) of action, but also about the biology present at the sites of drug localization 
relating to treatment efficacy213. 
Matrix-assisted laser desorption ionization (MALDI) is by far the most popular ionization 
technique used to map the tissue microenvironment. In this way, molecular 
classification can be accurately established with different tissue types, including tumors, 
to improve the accuracy of diagnosis and characterize tumor heterogeneity210. MALDI-
MSI allows in situ tissue characterization at different molecular “omics” levels—
metabolomics, lipidomics, peptidomics and proteomics214—and has found numerous 
clinical applications, including  oncology215, psychiatric and neurodegenerative 
disorders216-218, cardiovascular diseases219, 220, ophthalmology221, joint and cartilage-
related disorders222. Extensive efforts focused on instrument development to improve 
spatial resolution, throughput, and sensitivity have placed MALDI-MSI in a competitive 
position for clinical studies where knowledge about the tumor microenvironment is 
critical and hundreds of samples require analysis223-225. One of the drawbacks of MALDI-
MSI is the need for the application of homogenous layers of MALDI matrix on the tissue 
surface and the ion suppression resulting from the extraction process. This is in part due 
to the lack of separation technology in an imaging experiment and can degrade the 
sensitivity and quality of data generated.  
Recently, ambient ionization techniques have proven their suitability to extract relevant 
information from complex biological matrices226. The main benefit of these techniques 
is the possibility to analyze directly surfaces with relatively less complex and time-
consuming sample preparation compared to MALDI. This considerably reduces sample 
handling and speeds up the whole analytical workflow. Desorption electrospray 
ionization (DESI)117, 227 is increasing its application in clinical research as it provides 
relatively fast, sensitive, and complementary analysis to MALDI-MSI144, 228-233. DESI allows 
rapid classification of human tumors based on tissue-specific lipid molecular profiling234. 
One of the most promising applications would be to use the information at the time of 
surgery on resected specimens to guide surgical resections that could improve 
management of patients235. Liquid extraction surface analysis (LESA) based on a liquid  
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microjunction (LMJ) surface sampling was introduced in 2008 and has been employed 
for profiling biological matrices from localized tissue area in various studies, including 
drug distribution and metabolism122, 123, 148, 153, 236, microbiology237, small molecule 
antibody–drug conjugate catabolites238, lipidomics236, 239, proteomics240-242, and native 
mass spectrometry for non-convalent complex studies243, 244. Although often criticized 
for the poor spatial resolution achievable (i.e., 1.2–2.0 mm with 1 µL of solvent 
deposited on the top of the surface), LESA is an excellent tool for conducting profiling 
experiments from a selected spot, such as quick metabolite screening or parent drug 
localization to an organ. Complementary to quantitative whole-body autoradiography 
that provides distribution information on radiolabeled material, LESA followed by MS 
detection enables differentiation of a parent drug from its metabolites.  
Chromatography-free approaches create ion suppression effects, which enables the 
identification of analytes of high abundance245 but limits protein/peptide identification 
because of the high degree of cell or tissue complexity. Frequently, compounds are co-
desorbed and observe interference from structural isomers and/or isobaric compounds 
(e.g., interfering isotopic clusters). As a result, chromatography-free approaches often 
suffer from the absence of separation before the mass analysis. Indeed, high resolution 
is not adequate to distinguish isomers and in some cases tandem mass spectrometry 
(MS/MS) does not provide enough selectivity. Therefore, additional information and 
improved selectivity are required to provide adequate identification of biologically 
relevant analytes. The addition of a post-desorption and post-ionization gas-phase ion 
mobility spectrometry (IMS) after MALDI, DESI, and LESA has demonstrated to resolve 
isobaric species and reduce chemical noise122, 228, 246. However, this method does not 
account for tissue-specific ionization suppression245. Because the surface sampling and 
the ionization processes are resolved both in space and time dimensions, LESA allows 
for the manipulation of the extracted material in the liquid phase prior to ionization of 
molecular content247. As a consequence, LESA can easily incorporate a liquid-based 
separation after the surface sampling process, which is not possible with MALDI or DESI 
ionization techniques. Kertesz et al. developed a LMJ-SS approach followed by HPLC-
ESI-MS for the analysis of drugs and metabolites in whole-body thin tissue sections, 
which helps to distinguish isomeric phase II metabolites of propanolol123. Continuous-
flow LMJ-SS coupled online with HPLC/MS also enables the extraction, separation, and 
detection of proteins and low-molecular-weight compounds (e.g., drugs of abuse) from 
tissue sections and dried blood spots. Usually, the surface of dried blood spots is 
sufficiently hydrophobic for maintaining a stable liquid junction, even with high-
aqueous-content solvents135. This innovative LMJ-SS-HPLC-MS/MS approach was also 
used to investigate the distribution of specific markers within normal human pituitary 
gland and pituitary adenoma tissue sections, to discriminate between tumor and non-
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tumor tissues248. However, such targeted approach requires sample cleanup prior to 
analysis and will not allow broad screening for potential biomarkers. 
 
 
Figure 2.1 Schematic representation of flow connections between the elements of the µLC system (in grey) 
and the automated sampler device (blue). Main features of the analytical platform are indicated in green. The 
route of the sample loop is shown in red. The 6-port valve is in the “sample loading” position. HR: high spatial 
resolution. LESA: liquid extraction surface analysis. BSM: binary solvent manager. 
 
In the present work, we describe a platform developed to improve both poor spatial 
resolution achieved with “conventional” LESA and ionization suppression effect. The 
platform was modified for high-resolution (HR)-LESA for direct analysis of endogenous 
peptides from a 400-µm area from pre-clinical tissue samples249. The HR-LESA was 
integrated with an online washing step to remove salts and other contaminants, the 
key source of ion suppression. Micro-LC (µLC) was used to separate the analytes of 
interest from endogenous sample matrix compounds, an additional source of ion 
suppression. This platform allows isomeric separation due to the implementation of µLC 
further improved by ion mobility. After this µLC separation, the compounds were 
analyzed by MS, which combines IMS with MSE, a data-independent acquisition 
method. Finally, we automated the entire HR-LESA-µLC-IMS-MSE platform by 
implementing new software. This platform is presented here as a complementary 
addition to the field of mass spectrometry imaging since it opens doors to a more in-
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2.2 Experimental section 
Chemicals and reagents 
ULC/MS-grade water, ULC/MS-grade acetonitrile (ACN), and 99% formic acid were 
purchased from Biosolve (Valkenswaard, NL). Microscopic glass slides were purchased 
from Thermo Scientific (Braunschweig, DE). Leucine enkephalin standard was provided 
by a Waters Q-TOF Qualification Standards Kit (Etten-Leur, NL) and prepared at a 
concentration of 5 ng/µl in ACN/water (50/50; v/v) and used as lock mass. 
 
Murine tissue sectioning  
Healthy Wistar Han rat pituitary gland tissue samples were provided by the Department 
of General Surgery of the Maastricht University Medical Center (MUMC+). The fresh-
frozen wild type and  transgenic APP KM670/671NL/PS1L166P mice were supplied by the Bio-
Imaging Lab, University of Antwerp. Tissues were cryo-sectioned (Microtome cryostat 
Thermo Scientific, Braunschweig, DE) into 12-µm-thick tissue sections and subsequently 
thaw-mounted on regular microscope glass slides. These tissue sections were stored at 
-80 °C prior to analysis. Right before the analysis, samples were thawed at room 
temperature and desiccated for 30 min. Hematoxylin and eosin (H&E) staining was 
performed on these tissue samples after HR-LESA-µLC-IMS-MS analysis. 
 
H&E staining protocol 
H&E staining was performed on the same sections used for HR-LESA-µLC-IMS-MSE 
experiments. After MSI analysis, the residual matrix was gently removed by dipping the 
glass slides in ethanol (EtOH) for 2 minutes. Sections were then washed in successive 
bathes (96% EtOH, 70% EtOH and deionized water – 3 min each). The hematoxylin 
(Merck, Darmstadt, Germany) staining was then performed for 3 min, slides were then 
washed in gently running tap water for 3 min, followed by eosin staining for 30 s, 
washing under running tap water for 1 min and finally immersed in 100% EtOH for 2 
min. Slides were finally dehydrated in Xylene (30 s), covered in Etallen and coverslipped. 
The optical images were acquired using a MIRAX Desk scanner (Zeiss, Gottingen, 
Germany). Images were acquired with a magnification of 40. 
 
Conventional LESA extraction 
The LESA extraction was performed using the automated TriVersa NanoMate Advion 
robot (Advion, Ithaca, NY). A 0.5-µL volume of the extraction solvent (ACN/water/formic 
acid, 70/30/0.1 v/v/v) was deposited with a conductive pipette tip onto the tissue section 
for 5 s repeated 1 times. This extract was directly infused into the mass spectrometer 
(Waters Synapt G2-Si, USA) using chip-based nano-ESI, by applying a nitrogen gas 
pressure of 0.3 bar and voltage of 1.40 kV.  
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HR-LESA extraction, online washing, and µLC separation 
High spatial resolution extraction was performed using the capillary extraction arm 
usually used for coupling with LC-MS fraction collection. Extraction with this setup was 
performed with 0.5 µL extraction solvent (ACN/water/formic acid, 70/30/0.1 v/v/v) after 
5 s in contact with the tissue section. An online and automated buffer exchange was 
then performed, by diluting 10 times the sample with the carrier solvent 
(ACN/water/formic acid, 5/95/0.1 v/v/v) – to ensure compatibility with reversed-phase 
chromatography – and collected in a 3-µL loop (Figure 2.1). Under these conditions, the 
local extraction was achieved at a spatial resolution of 400 µm, and the total workflow 
from extraction solvent aspiration to filling in the sample loop takes ~3 min. Following 
this extraction, the sample was trapped onto a trap column (ACQUITY UPLC M-class 
Symmetry C18, 100 Å, 5 µm, 300 µm × 50 mm, Waters, USA) and washed with the 
carrier solvent for 2 min to remove salts and other possible interferences/contamination. 
After the 2-min online washing, the trap column was back-flushed onto the µLC IonKey 
column (iKey BEH C18 Separation Device, 130 Å, 1.7 µm, 150 µm × 50 mm, Waters, 
Milford, MA) for chromatographic separation as follow: a 13-min gradient from 1% to 
85% solvent B (ACN/formic acid, 100/0.1) was used for elution of peptides. The column 
was washed for 3 min at 85% solvent B prior to the column equilibration at 1% solvent 
B for 5 min. The trap column was equilibrated at 1% solvent B for 4 min. 
 
Mass spectrometry 
All MS experiments were conducted on a Waters Synapt G2-Si system operated in 
positive ionization mode (in sensitivity mode). General operating parameters were: 
capillary voltage = 4 kV; source temperature = 80 °C; sampling cone voltage = 40 V; 
and a desolvation temperature = 150 °C. The default collision energy was set at 4 eV 
in full MS scan mode. IMS was performed using nitrogen as a drift gas at a flow rate of 
90 mL/min. The TRAP DC entrance was set to 0 V and the wave height was set to 40 
V. The velocity of the IMS wave was used to separate the ions over the total 200 ms. 
The start velocity was set at 1200 m/s and the end velocity at 400 m/s. Data-
independent IMS-MSE acquisition was conducted for the analysis of the pituitary gland 
and further identification of extracted endogenous peptides. These measurements were 
performed in the TRANSFER T-wave using a collision energy ramp from 20 to 45 eV. 
The detector voltage was set at 2500 V, and data was acquired within a mass range of 
m/z 50–2000.  
 
Software 
The LESA extraction was controlled by a beta version of the LESA Plus software (Advion, 
UK), and MassLynx 1.4 (Waters, USA) was used for controlling the online washing step 
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and the µLC separation. Data were processed and visualized using Mass Lynx 1.4 
(Waters, USA) and DriftScope v2.5 (Waters, USA). The identification of the 
neuropeptides and proteins was performed using Progenesis QI for proteomics 
v2.0.5556.29015 (Non Linear Dynamics, USA). For this identification, a species-specific 
FASTA file was created, and non-specific digest reagent was selected. The amount of 
missed cleavages was set at 3 and the post-translational modifications (PTMs) allowed 
in this MSE search were N-acetylation, M-oxidation, and C-carbamidomethylation.  
 
2.3 Results and discussion 
Here, we describe the HR-LESA-µLC-IMS-MS platform and its performance for spatial 
analysis of neuropeptides. For this purpose, two animal models were used. The first 
experiments rely in the investigation of neuropeptides in rat pituitary gland tissues, 
which consists of two different regions with different biological functionalities: the 
adenohypophysis (anterior lobe and intermediate lobe) and the neurohypophysis 
(posterior lobe). Therefore, due to the morphology of the tissue (~ 2 x 3 mm), local 
extraction at high spatial resolution is crucial for molecular characterization of both 
regions. The second set of experiments is performed on wild type and transgenic mice 
expressing amyloidosis to assess the potential of the platform to study neuropeptides 
potentially involved in Alzheimer’s disease progression. In this case, the sampling areas 
include regions with high expression of amyloidosis, such as the cerebral cortex, 
hippocampus and cerebellum, which also require precise sampling.  
 
Analytical platform 
Spatial resolution. In a conventional LESA set-up, the extraction is achieved using a 
conductive pipet tip – which, depending on the solvent composition, can lead to a large 
sampled area up to 2 mm130. This is potentially a limiting factor when analyzing small 
objects such as the anatomical features of the pituitary gland or any other organs that 
require precise sampling. In our HR-LESA-µLC-IMS-MS platform (Figure 1), we modified 
the extraction system to improve the spatial resolution and reduce the size of the 
extracted areas. By using a silica capillary instead, we were able to significantly improve 
the spatial resolution to 400 µm – as assessed under microscopic evaluation of the tissue 
section after the liquid extraction took place (Figure 2). With an extracted area of 400 
µm, the molecular content from the anterior and posterior lobe of the pituitary gland 
can be accurately extracted. We illustrate the ability to unambiguously distinguish 
between the adenohypophysis and neurohypophysis of the pituitary in Figure 2. Equal 
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Figure 2.2 H&E stained images of the pituitary gland before (a) and after (b) HR-LESA extraction show an 
improvement in spatial resolution with HR-LESA (i.e. 400 µm area represented by a green dot in b) compared 
to conventional LESA (area shows the spot size of a typical LESA extraction (i.e., 1000 µm-diameter, red circle 
in b)). In (b), the arrow indicates the trace after an extraction with the capillary. Anatomical features of the 
pituitary gland containing the adenohypophysis and the neurohypophysis. Anatomical features: 1. Anterior 
lobe; 2. Posterior lobe; 3. Intermediate lobe. 
 
Reproducibility of the extraction. To investigate the extraction reproducibility and 
sample carry-over of the HR-LESA setup, extraction of a leucine enkephalin standard 
was performed followed by flow injection analysis. A 5-ng leucine enkephalin solution 
(prepared in ACN/H2O; 50/50; v/v) was spotted onto a hydrophobic plate and air-dried. 
The extractions of 5 consecutive spots using 0.9 μL of 50% ACN + 0.1% HCOOH and 
the modified HR-LESA extraction system resulted in a coefficient of variation of 30% 
(based on the surface area from the extracted ion chromatogram at m/z 556.28 
(protonated species [LeuEnk + H]+) for each extracted spots; n=5; Figure 2.3).  
 
 
Figure 2.3 Evaluation of the reproducibility of the extraction with the silica capillary probe followed by FIA. 
Results display XIC at m/z 556.28 (protonated Leucine-Enkephalin ion [LeuEnk + H]+) for one blank (glass 
slide) followed by 5 extractions of LeuEnk using 0.9 μL of 50% ACN + 0.1% HCOOH. Photograph displays 
the silica capillary probe during the extraction from the plate. CV based on absolute area (n=5). 
 
Integration of online clean up between extraction and chromatographic separation. The 
tissue sample was placed in the sample plate holder as shown in the photograph in 
Figure 2.1. This tissue extract was then collected in a 384-well plate and diluted with 
carrier solvent. The diluted extract was ‘injected’ by the same fused silica capillary, 
collected in the 3-µL loop, and, after switching the 6-port valve, trapped onto the C18 
trap column for an online washing with water/ACN (99/1; v/v) to remove all water-
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soluble matrix compounds. The trap column was back-flushed to separate the 




Figure 2.4 Reproducibility of LESA-µLC-MS platform using leucine enkephalin standard spotted onto 
hydrophobic plate. Three extracts were taken, followed by two blank extracts. The relative standard deviation 
of the retention time of the leucine enkephalin extraction is <0.12% (n=3). The carry-over in the first blank 
extraction is <1.1% considering the absolute peak area of the last leucine enkephalin extraction versus the 
absolute peak area of the first blank extraction. 
 
Reproducibility of the chromatographic separation and sample carry-over. HR-LESA 
combined with the online washing and µLC separation IonKey system was evaluated. 
The chromatographic peak of leucine enkephalin was found at a retention time of 16 
min. This extraction was performed in triplicate to test the retention time reproducibility 
followed by two blank extractions to study carry-over. The relative standard deviation 
of the retention time was < 0.12 % and the carry-over in the first blank extraction was 
< 1.1 % using the absolute peak area, which demonstrates a good reproducibility of 
chromatographic separation (Figure 2.4). The minimal occurrence of sample carry-over 
was due to the online clean-up of the sample loop during the analysis. In addition to 
the leucine enkephalin standard extraction, reproducibility of the chromatographic 
separation of neuropeptides from mouse brain and corresponding carry-over has been 
investigated (Figure 2.5a and 2.5b). Relative standard deviation values vary from 7.1% 
to 25.4% and the sample carry-over is <0.8% (Figure 2.5c-2.5f and 2.6). These values 
were obtained from three tissue extractions followed by a blank extraction in use of the 
absolute chromatographic peak area. While the implementation of µLC into our 
platform significantly minimizes the amount of ionization suppression, the 
reproducibility could be considerably improved by the addition of an isotope-labelled 
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Figure 2.5 Reproducibility and isobaric separation of HR-LESA-µLC-IMS-MSE platform using APP and WT 
mouse brain tissues. Three extracts from each tissue section were taken from the cerebral cortex region, 
followed by one blank extract from the glass slide. For the reproducibility test, XIC are shown of m/z 634.38 
at 6.02 ms arrival time from APP brain (a) and WT brain (b). The relative standard deviation for the three 
extractions (n=3) considering the peak areas are 7.1% (a) and 13.3% (b). For the isobaric separation, the XIC 
of two neuropeptides are shown of m/z 587.35 from APP brain with corresponding mass spectrum at 
retention time 16.36 min with 5.33 ms arrival time (c) and 21.23 min with 8.17 ms arrival time (d). The relative 
standard deviation of the three extractions (n=3) at retention time 16.36 min and 21.23 min are 9.3% (c) 
and 25.4% (d), respectively. Carry-over was assessed by dividing the absolute peak area of the last brain 
extraction (green) by the absolute peak area of the following blank extraction (purple). Carry-over values 
were: 0.6% (a), 0.7% (b), 0.8% (c) and 0.7% (d). The asterisk (*) corresponds to m/z used to extract the ion 
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Figure 2.6 Isobaric separation of neuropeptides in the cerebral cortex region of APP mouse brain. Three 
extractions were performed from the tissue section, followed by one blank extract from the glass slide. XIC 
are shown of m/z 587.35 from APP brain (a) with corresponding mass spectrum at retention time 16.36 min 
(b) and 16.57 min (c) both at 5.26 ms arrival time.  The relative standard deviation of the three extractions 
(n=3) at retention time 16.36 min and 16.57 min are 9.0% and 14.4%, respectively. Carry-over was assessed 
by dividing the absolute peak area of the last brain extraction (green) by the absolute peak area of the 
following blank extraction (purple). Carry-over values were: 0.5 % (at 16.36 min) and 0.1% (at 16.57 min). 
The asterisk (*) corresponds to m/z used to extract the ion chromatogram (XIC).  
 
Post-surface sampling chromatographic separation 
Having demonstrated that the HR-LESA provided higher spatial resolution, good 
reproducibility, and minimal sample carry-over, we implemented a µLC separation to 
enable isomeric separation and further sample cleanup. Isomers have the same mass 
and the same molecular formula, in contrast to isobaric compounds, which have the 
same nominal mass but differ in molecular formula. MS alone is insufficient to separate 
and accurately identify isomeric compounds (even with high mass resolution 
instrumentation). Furthermore, ion suppression often occurs and is considered the 
primary cause of irreproducibility in MS. Because LC is a powerful tool for separation of 
these isomeric compounds130, we integrated an online washing step and µLC separation 
after the surface sampling and prior to electrospray ionization (Figure 2.1). Compared 
to conventional LESA, the HR-LESA approach with online washing and µLC separation 
showed an increase in sensitivity and selectivity for leucine enkephalin in the 
adenohypophysis region of rat pituitary online (Figure 2.7). When we performed our 
HR-LESA-µLC-IMS-MSE approach for the analysis of pituitary, 67 compounds could be 
chemically identified while only 5 and 4 compounds could be found in the conventional 
LESA-IMS-MS and LESA-MS data, respectively137. For the mouse brain cerebral cortex 
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analysis, 14 compounds could be identified with HR-LESA-µLC-IMS-MSE while only 3 
and 2 compounds were observed in the conventional LESA-IMS-MS and LESA-MS data, 
respectively. In view of the even larger spot size of LESA-MS, the minimization of 
ionization suppression by µLC is crucial for detection of lower abundant compounds. 
Although the implementation of µLC in our approach requires a longer analysis time 
(30 min/spot) compared to conventional LESA-MS (1 min/spot), this can be justified due 
to the enhanced detection limits of the HR-LESA-µLC-IMS-MSE platform compared to 
conventional LESA-IMS-MS and LESA-MS. 
 
 
Figure 2.7 Sensitivity of LESA-MS versus HR-LESA-µLC-MS: The total mass spectrum (a and c) and a zoomed-
in mass spectrum (b and d) of the adenohypophysis region of rat pituitary gland using LESA-MS (a and b) 
compared to HR-LESA-µLC-MS (c and d). The zoomed mass range displays a low-intensity peak corresponding 
to the protonated molecule of leucine enkephalin (marked with *), which is known to be present in this 
region. This is extracted from the ion chromatogram at retention time at 16 min. The zoomed mass range 
from HR-LESA-µLC-MS shows the presence of leucine enkephalin co-eluting with a triply charged species, 
which was not observed with LESA-MS. 
 
Interestingly, in the pituitary data, we observed the presence of a triply charged species 
(Figure 2.7d) co-eluting with the leucine enkephalin, which was not detected with the 
conventional LESA extraction (Figure 2.7b). This difference can be explained by the 
occurrence of ion suppression, which was minimized by HR-LESA-µLC-MS. The 
extracted ion chromatogram (XIC) based on the protonated molecule signal of leucine 
enkephalin (m/z 556.28 ± 0.05) extracted from the adenohypophysis region showed a  
retention time of 16 min, similar to that of the monoisotopic peak of the triply charged 
species  (m/z 555.65, Figure 2.7a). 
However, the corresponding mass spectrum shows a different isotope pattern 
belonging to a triply charged species (Figure 2.8b, green asterisk). This clearly exposes 
the limitations of LC separation and need for additional separation power to increase 
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selectivity and accurate identification. For this reason, an additional gas-phase IMS was 
added to the analytical workflow to increase the analytical content of the data.  
 
 
Figure 2.8 The extraction of two co-eluting compounds: the XIC (a) and corresponding mass spectra (b). The 
green XIC represents the chromatogram extracted from the monoisotopic peak of the triply charged species 
at m/z 555.65. The red XIC represents the chromatogram extracted from leucine enkephalin at m/z 556.28. 
 
Ion mobility spectrometry (IMS) of isobaric species 
We employed tri-wave ion mobility to achieve additional separation: the TRAP T-Wave 
region was used for trapping and accumulating ions, IMS T-Wave region for subsequent 
separation, and the TRANSFER T-Wave region to focus the ions and as fragmentation 
cell when performing data-independent IMS-MSE measurements. IMS was performed 
from the anterior lobe HR-LESA extraction (m/z 556.28 eluting at tR = 16 min; Figure 
2.9a). The extracted ion mobility arrival time spectrum (Figure 2.9b) depicts two arrival 
time peaks, which can be labelled using the corresponding mass spectra as leucine 
enkephalin (Figure 2.9d) and its co-eluting compound (Figure 2.9c). The mass spectra 
extracted at this specific retention time displayed clean signals with overall improved 
sensitivity. The observed isotope pattern of the triply charged species has a mass of 
1664 Da after deconvolution. The advantage of the integration of IMS after 
chromatographic separation is the additional separation power that is gained to 
separate co-eluting isomeric species, without compromising the overall analysis time. 
For the identification of this co-eluting species and other extracted proteins, IMS-MSE 
analysis was performed. IMS-MSE is a data-independent acquisition (DIA) mode that 
includes both high and low collision energy measurements alternated in one parallel 
analysis using the retention time to match precursor and fragment ions. Species can be 
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identified in one analysis without requiring additional data-dependent MS/MS 
experiments by performing IMS-MSE analysis. 
 
 
Figure 2.8 The ion mobilogram (a) of the extract from the anterior lobe of pituitary gland is depicted. The 
extracted ion mobility arrival time spectrum (b) shows the separation of two co-eluting compounds. The 
extracted mass spectra at arrival time 3.8 ms (c) and 5.6 ms (d) show the separation of both compounds, 
indicated in red (leucine encephalin) and green (N-acetylated alpha-melanocyte stimulating hormone). 
 
Identification of neuropeptides and proteins present in the pituitary gland 
We sought to identify neuropeptides and proteins in the rat pituitary samples using our 
platform by integrating data-independent acquisition (DIA). We chose the DIA approach 
because data-dependent acquisition (DDA) often neglects low-abundance precursor 
ions, which limits the discovery of untargeted analytes and markers250. One DIA 
approach, MSE, collects TOF mass spectra with and without fragmentation by 
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alternating the energy of the collision cell between low and high values250. Another 
approach, sequential window acquisition of all theoretical fragment-ion spectra 
(SWATH), was developed on hybrid Q-TOF mass analyzers that offer resolving power of 
20,000–40,000251. Both approaches were demonstrated to be particularly powerful in 
detecting low-abundance analytes for further metabolite and peptide identifications. 
We integrated IMS-MSE acquisition into our platform. 
 
IMS-MSE detects both precursor ions and fragments of the precursor ions fragmented 
independently on their abundance252. Progenesis QI for proteomics software uses an 
algorithm that also performs a database search considering retention time, mass 
accuracy, and PTMs250. However, due to the DIA nature of these analyses, this algorithm 
is based on physicochemical properties of the peptides and proteins. These 
characteristics are used to calculate the correlation to models with regards to 
hydrophobicity and gas-phase separation and are, therefore, applicable to reversed-
phase LC and IMS. In similar strategy to DDA to calculate false-positive identification 
rates, we applied decoy and species-specific databases. Sensitivity and selectivity are 
significantly increased because of the repetitive approach of this algorithm. After the 
identification of the most abundant protein, this data is removed from the database, 
and another search is executed to identify the second most abundant protein. After 
removing the data from the second most abundant protein, a third search is performed. 
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Figure 2.10 Intact protein extracted from the adenohypophysis region of the pituitary gland. Deconvolution 
of the mass spectrum allowed determining the mass of an intact protein at 21832 Da. This protein was 
identified as POMC. 
 
 










Q7TNJ2 1 1 2.7696 ATP-binding cassette sub-family A member 7  
P01186 17 17 155.3358 Vasopressin-neurophysin 2-copeptin  
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Q2TA51 1 1 3.90 Keratin-associated protein 5-5 OS=Mus musculus GN=Krtap5-5 PE=2 
SV=1 
P43277 3 2 8.71 Histone H1.3 OS=Mus musculus GN=Hist1h1d PE=1 SV=2 
Q64507 1 1 3.31 Keratin-associated protein 5-1 OS=Mus musculus GN=Krtap5-1 PE=2 
SV=1 
Q8VI56 1 1 2.08 Low-density lipoprotein receptor-related protein 4 OS=Mus musculus 
GN=Lrp4 PE=1 SV=3 
P43275 1 1 3.34 Histone H1.1 OS=Mus musculus GN=Hist1h1a PE=1 SV=2 
Q8C0Q3 1 1 2.76 Tetratricopeptide repeat protein 34 OS=Mus musculus GN=Ttc34 PE=2 
SV=2 
O55111 1 1 4.30 Desmoglein-2 OS=Mus musculus GN=Dsg2 PE=1 SV=3 
P54320 2 2 8.74 Elastin OS=Mus musculus GN=Eln PE=1 SV=2 
Q9JHT5 1 1 4.47 AMME syndrome candidate gene 1 protein homolog OS=Mus musculus 
GN=Ammecr1 PE=2 SV=1 
P43276 1 0 4.90 Histone H1.5 OS=Mus musculus GN=Hist1h1b PE=1 SV=2 
 
In the extracts from the rat pituitary gland, we identified vasopressin and POMC (Figure 
2.10), based on 17 and 25 peptides, respectively (Table 2.1)250. These peptides, which 
are deriving from the pro-opiomelanocortin (POMC) precursor protein, are important 
signaling molecules in regard to feeding behavior and, therefore, involved in diseases 
like obesity, bulimia, and anorexia nervosa253, 254. In the mouse brain cerebral cortex 
extracts, we identified 14 peptides (Table 2.2). After applying de novo peptide 
sequencing to the fragmentation spectrum of the co-eluting species at m/z 1664 at the 
retention time of 16 min, this compound was identified as N-acetylated alpha-
melanocyte stimulating hormone based on nine fragment ions: y1, b1, y2, y7+2, y5, y10+2, 
y12+2, y7, and y8, deriving from P01194 (124–136). The MS/MS spectra can be found in 
Figure 2.11 (a and b). Based on the MSE data, the singly charged species was identified 
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Figure 2.11 MSE data and fragments of alpha-MSH (precursor m/z 555.65, +3) extracted from the pituitary 
gland. Spectra are shown at high (a) and low (b) collision energy after background subtraction. Fragments 
from the triply charged precursor were identified as follows: m/z 117.07 (y1 ion), m/z 131.03 (b1 ion), m/z 
214.17 (y2 ion), m/z 444.79 (y7 ion; +2), m/z 555.65 (precursor; +3), m/z 585.33 (y5 ion), m/z 643.39 (y10 
ion; +2), m/z 768.43 (y12 ion; +2), m/z 832.99 (precursor; +2), m/z 888.58 (y7 ion), and m/z 1025.65 (y8 
ion). This data correlates with previously published data presented255. MSE data and fragments of leucine 
enkephalin (precursor m/z 556.28, +1) extracted from the pituitary gland. Spectrum is shown at high collision 
energy at 6.02 ms arrival time after background subtraction. Fragments from the triply charged precursor 
were identified as follows: m/z 91.06, m/z 119.06, m/z 177.18, m/z 221.14 (b2 ion), m/z 397.23 (a4 ion) and 
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2.4 Conclusion 
This work reports the development of an automated and integrated platform combining 
the advantages of both spatial sampling with LESA and chromatographic separation 
(µLC) for the direct analysis of tissue sections with potential clinical, pre-clinical 
relevance. In addition, the platform was strengthened by the integration of ion mobility 
spectrometry (IMS) and data-independent acquisition (DIA) for both the separation and 
the identification of neuropeptides from a complex tissue extract from a 400 µm area. 
Improvement over conventional LESA of the spatial resolution capabilities of the 
surface-sampling process was achieved, down to a spatial resolution of 400 µm, by 
modifying the sampling probe. The platform demonstrated strong reproducibility, 
minimal carry-over, increased sensitivity, technical reproducibility, and identification of 
isobaric compounds. 
 
The advantages of this integrated platform hold strong potential for pre- and clinical 
applications. Currently, the extraction efficacy is limited to soluble proteins with the 
number of protein and peptide identifications at fewer than 500. In particular, low-
abundance analytes can be identified in complex and small tissue samples, as 
demonstrated with rat pituitary and mouse brain here. Information about protein 
isoforms, important in many neurodegenerative diseases, is predicted to be elucidated 
with the application of our platform with classical in-gel proteomics241. This approach 
paves the way for imaging researchers to increase the total number of proteins and 
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High resolution Ion Mobility Spectrometry (IMS) based on linear ion transport in low-to-
moderate electric fields and nonlinear ion transport in strong electric fields emerges as 
a broad approach for rapid separations prior to mass spectrometry (MS). Here we 
present a comparison of three high resolution IMS techniques: linear cyclic IMS, linear 
Trapped IMS, and nonlinear high-Field Asymmetric Waveform IMS for the isomeric 
separation endogenous detection of prostanoids present in intestinal tissue. Inefficiency 
in negative ionization mode ESI for these compounds (due to low proton affinity of 
carboxylic group) was overcome by derivatization with Girard’s reagent T. Multiple 
isomers with distinct in vivo function crucial to understand the inflammation process, 
including the prostaglandins E2 (PGE2) and D2 (PGD2) were included in our IMS 
comparison. Strengths and weaknesses of both linear and nonlinear IMS were revealed 
and discussed in which linear IMS provided the best sensitivity and nonlinear IMS the 
best resolution. This work portends well for high resolution IMS-MS as a powerful 
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3.1 Introduction 
The inflammation process plays a key role during disease development, including 
arthritis, cardiovascular disease and cancer; and is often at the center of multiple 
investigations. As a counter reaction to inflammation, an immune response triggers 
increased amounts of mast cells releasing histamine, tryptases, and eicosanoids, which 
are implicated in the heat and swelling256, 257. Eicosanoids, in particular prostanoids, are 
of interest due to their pro-inflammatory properties and increased presence in inflamed 
tissue. Prostanoids are products derived from arachidonic acid after its release from the 
sn-2 position of membrane phospholipids through the action of phospholipase A2. 
Prostaglandin G/H synthases (PGHS), often referred to as cyclooxygenase (COX), further 
catalyzes the reaction towards the intermediate prostaglandin H2258, 259. This 
intermediate prostaglandin is then, depending on the activity of the associated enzyme, 
converted into one of the active prostanoid end products (Figure 3.1): Prostaglandin D2 
(PGD2), Prostaglandin E2 (PGE2), Prostaglandin F2a (PGF2a), Prostaglandin I2 (PGI2), or 
Thromboxane A2 (TxA2)260, 261.  
 
 
Figure 3.1 Molecular structures of 5 prostanoid end products of the COX pathway: PGD2 (a), PGE2 (b), PGF2a 
(c), PGI2 (d), and TxA2 (e). 
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This COX pathway can be separated into two different pathways, COX-1 and COX-2, 
due to the existence of different isoforms of the PGHS. The end products of COX-1 and 
COX-2 have a similar structure but play a significantly different role in the biology. With 
taking exceptions into account, one could state that in general the COX-1 pathway is 
responsible for fundamental prostaglandin synthesis while COX-2 is involved in the 
prostaglandin production due to inflammatory response258. In bioanalytical studies, this 
distinction between COX-1 and COX-2 is crucial.  
Conventional liquid chromatography tandem mass spectrometry (LC-MS/MS) profiling 
platforms have been developed for (high-throughput) screening of eicosanoids in 
biological samples262-264. Most of these platforms require time-consuming sample 
preparation steps and chromatographic separation for isomeric compounds (e.g. PGE2 
and PGD2). In addition, the free carboxylic acid groups of the eicosanoids offer very 
poor ionization efficiency in negative ionization mode265. Therefore, derivatization 
strategies of eicosanoids have been employed successfully to increase ionization 
efficiency for analysis in positive ionization mode266. Some of these derivatization 
reagents, such as Girard’s reagent T, target the carbonyl group which present in 
prostanoids. The analysis of choice for eicosanoid screening requires efficient ionization, 
high sensitivity and selectivity in complex biological samples, combined with powerful 
stereoisomeric separation. The latter is demanded due to the substantial impact of 
stereoisomerism on the biological activity of eicosanoids. For this reason, 
chromatography is often chosen for eicosanoid analysis267, 268. 
As an alternative to chromatographic separation approaches, ion mobility spectrometry 
(IMS) offers a separation technology in which ions are electrically driven through a 
buffer gas55, 269. IMS has shown its potential for isomeric separation while removing 
background from complex biological samples270. There are several different IMS 
technologies available: Drift Tube IMS (DTIMS)271, 272, Traveling Wave IMS (TWIMS)58, 273, 
Trapped IMS (TIMS)63, 64, and high-Field Asymmetric Waveform IMS (FAIMS; also known 
as differential IMS or DMS)67. IMS is already widely used in the field of proteomics52, 274, 
lipidomics228, and metabolomics275, 276. Dwivedi and coworkers presented a screening 
method for a wide range of metabolites (including eicosanoids) using DTIMS275. This 
work proved to separate isobaric eicosanoids but still lacks sufficient ion mobility 
resolving power for isomeric separation (e.g. PGE2 and PGD2). Higher ion mobility 
resolving power is necessary for the separation of structural eicosanoid isomers. From 
the different types of IMS, three IMS techniques have shown high ion mobility resolving 
power: cyclic IMS (R<300), TIMS (R<300) and FAIMS (R<500)277. Cyclic IMS (cIMS) is 
based on the TWIMS principle58 but prolongs the path of the IMS cell by a loop 
configuration278. Ions can pass this IMS loop multiple times and, therefore, increase their 
total path length. The amount of passes can be adapted to the separation required. 
Researchers have recently investigated cIMS for polymer analysis279, RNA 
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modifications280, and carbohydrates281. TIMS applies a reversed principle compared to 
cIMS. TIMS uses a buffer gas to introduce ions to the TIMS cell. These ions are trapped 
by applying a counteracting electric field while the buffer gas moves in the exit 
direction282. The ion trapping time is 10 ms up to 1 sec dependent on the separation 
power necessary64. Several TIMS applications have been reported on proteins283, 
peptides284, and small molecules285-287. FAIMS66, 67, 288 applies an asymmetric waveform 
(high and low electric fields) across two parallel plates to which gas-phase ions are 
introduced by a carrier gas277. This waveform comprises a short high-field positive and 
long low-field negative segments that integrate to zero over a period. Since the ion 
mobility (K) is different at Elow and Ehigh, the ion will tend towards one of the two plates65. 
A compensation voltage (CV; V) is superposed on the waveform to correct the ion’s 
trajectory and to prevent collision with one of the plates (deionization). Alteration of 
this CV allows selection of ions, with specific ion mobility differentials, to be transferred 
to the mass spectrometer. Scanning the CV is often expressed by a compensation field 
(Ec; V/cm) due to different plate distances used between FAIMS devices. FAIMS research 
has focused on protein analysis289-293, though applications can be found for analysis of 
glycans294, lipids246, 295, 296, and metabolites122.  
Advantages of cIMS, TIMS and FAIMS are not only the isomeric separation power but 
also its ability to significantly reduce chemical noise from complex samples, which is of 
particular importance when analyzing low-level endogenous eicosanoids. To our 
knowledge, only limited research is published using high resolution ion mobility 
separation for isomeric eicosanoid separation and, if so, it is used in combination with 
LC297. 
Here, we investigated the use of three IMS systems for the analysis of prostanoids in 
complex biological tissue, namely: linear cIMS, linear TIMS, and nonlinear FAIMS. 
Girard’s reagent T (GT), already used to derivatize both endogenous298-300 and 
exogenous110, 127 compounds, was assessed for derivatization of prostanoids which 
improves ionization efficiency in positive ionization mode and decreases possible ion 
suppression from the sample matrix. We hypothesize that the GT derivatization can 
assist in the improvement of ion mobility separation through an increased difference of 
collisional cross section. In this work, we performed an IMS comparison to test this 
hypothesis. We subsequently validated our approach by derivatizing mini pig intestine 
extracts with GT to investigate the endogenous detection of prostanoids. 
 
3.2 Experimental section 
Materials 
HPLC-grade water and HPLC-grade methanol (MeOH) were purchased from Fischer 
Chemical (Fair Lawn, NJ, USA). Reagent grade >95% formic acid and GT were acquired 
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from Sigma-Aldrich (St. Louis, MO, USA). All prostanoid standards were purchased from 
Cayman Chemical (Ann Arbor, MI, USA) and prepared to a 20 µM mixture in MeOH. 
Identification and FAIMS peak assignment was executed by direct infusion of individual 
standard at the same concentration (e.g. 20 µM in MeOH). Mini pig intestine tissue was 
provided by Janssen Pharmaceutica (Beerse, BE). Titan3, 17 mm filters with a pore size 
of 0.45 µm were purchased from Thermo Fisher (Rockwood, TN, USA). 
 
Direct infusion-MS 
Prostanoid concentrations used for direct infusion were concentrated to 1 µM in a 
MeOH/water solution (80/20; v/v). For analysis in positive ionization mode, 0.2% formic 
acid and 10 mg/ml GT was added to the prostanoid standard mixture. This mixture was 
incubated at room temperature for 5 minutes. Direct infusion experiments were 
performed on a high mass resolution (140,000 at m/z 200) Q-ExactiveTM orbitrap mass 
spectrometer equipped with a heated ESI source (HESI-II probe, Thermo Scientific). 
Negative and positive ions were generated at a 5 µl/min flow rate while applying a 
capillary voltage of 5.0 kV and 4.0 kV, respectively. The mass spectrometer operated in 
normal MS mode and MS/MS spectra were acquired using collisional induced 
dissociation (CID) fragmentation. The normalized collision energy applied was in the 
range of 35-40 arbitrary units depending on the compound fragmented. Data was 
acquired at a mass range of m/z 50-750 and recorded using Thermo Xcalibur Roadmap 
(Thermo Scientific, version 2.8).   
 
Tissue extract preparation 
Frozen mini pig intestine was received from Janssen R&D (Beerse, BE) and stored at -80 
°C. Eight, 500 µm thick sections were taken from the intestine sample at -21 °C using 
a Microtome cryostat (Thermo Scientific, Braunschweig, DE) and collected in a 1.5 ml 
Eppendorf tube. For the prostanoid extraction, 500 µl MeOH was added to the tube 
and 3 repetitive freeze-thaw cycles (10 min on dry-ice followed by 10 min sonication) 
were executed. After extraction, this sample was centrifuged (Eppendorf, 13000 rcf, 10 
min) to separate the supernatant from the lysate. Supernatant was collected in a clean 
1.5 ml Eppendorf tube and stored at -80 °C. Prior to the analysis, the thawed sample 
was centrifuged for 5 min and filtered over a 0.45 µm filter to prevent needle clogging 
during the nanoESI analysis.  
 
High resolution IMS-MS experiments 
Cyclic IMS. Samples were infused at a 3 ul/min flow rate into a prototype cIMS-MS 
instrument based on a modified SYNAPT G2-Si instrument (Waters Corporation, UK) 
after positive Nano-ESI ionization. The cIMS separator consists of a multifunction array 
of electrodes forming an orthogonal closed loop. The cIMS chamber has a path length 
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of 98 cm with a single pass revolving power of ~65. The velocity was set to 375 m/s 
and the T-wave height was 25 V. The TOF mass range was set to m/z 50-1000. Data 
was acquired and processed using a custom MassLynx data acquisition with new 
interactive instrument control software (Waters Corporation, UK). 
TIMS. Samples were introduced at a 3 ul/min flow rate into the TIMS-tof instrument 
(Bruker Daltonics, USA) and ionized using positive ESI. General ESI parameters were: 
capillary voltage 3.5 kV, N2 pressure at 0.8 bar (11.6 psi), drying gas flow rate of 4.0 
l/min, and a drying temperature of 200 °C. Voltages were applied at the entrance and 
exit of the TIMS tunnel, 255 V and 55 V, respectively. The tramp applied was 450 ms. 
Nitrogen was used as the TIMS drift gas. The TOF mass range was set to m/z 400-500. 
Data acquisition and processing occurred with Compass DataAnalysis v5.0 software 
(Bruker Daltonics, USA). 
FAIMS. NanoESI-FAIMS-MS experiments performed on a custom made FAIMS device65 
connected to an LTQ XLTM linear ion trap mass spectrometer (Thermo Scientific, 
Waltham, MA, USA) equipped with an ion funnel (Heartland Mobility)301. Negative and 
positive nanoESI occurred by infusion of the sample at a flow rate of 300 nl/min and a 
capillary voltage of 3.8 kV and 5 kV, respectively. FAIMS separation was carried out by 
two parallel plates distanced 1.88 mm apart, with a total path length of 4 cm. A 
bisinusoidal asymmetric waveform was created by an RF generator (Heartland Mobility) 
with a peak dispersion voltage of 4 kV. Carrier gas flow was produced and maintained 
by two digital flowmeters (MKS Instruments, Andover, MA, USA) in a He/N2 mixture 
(60/40) at a rate of 1.4-2 l/min. The CV was scanned at a rate of 0.33-1 V/min for both 
positive and negative ionization mode, from 178 to 158 V and -210 to -190 V, 
respectively. Subsequent to the FAIMS device, an ion funnel technology (Heartland 
Mobility) allowed to transmit and focus the ions generated for maximized sensitivity. 
Data was acquired at a mass range of m/z 100-600 and recorded by Thermo Xcalibur 
Roadmap (Thermo Scientific, version 2.2). 
 
3.3 Results and discussion 
Girard’s reagent T (GT) derivatization of prostanoids 
The GT reagent, used for the prostanoid derivatization, is frequently utilized for the 
reaction with aldehydes and ketones302. GT forms a hydrazone after an acid-catalyzed 
reaction with a carbonyl group and subsequent loss of water as described previously303-
305. This reaction occurs in a two-step mechanism in which the GT hydrazine first forms 
a carbinolamine intermediate followed by a dehydration reaction to form a hydrazone. 
This two-step reaction of GT with PGE2 is displayed in Figure 3.2a and 3.2b, respectively.  
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Figure 3.2 The formation of carbinolamine and hydrazine is shown in the two-step mechanism of Girard’s 
Reagent T (GT) derivatization of PGE2. Step 1: the carbonyl group and the GT form a carbinolamine (a). Step 
2: under the action of formic acid, a hydrazine is formed after a loss of water (b). 
 
Table 3.1 Prostanoid standard mixture and their exact m/z values. 
Compound [M-H]- (m/z) [M+GT]+ (m/z) 
PGD2 351.2177 466.3184 
PGE2 351.2177 466.3184 
13,14-dihydro-15-keto-PGE2 351.2177 466.3184 
PGF2a 353.2334 468.3340 
PGD1 353.2334 468.3340 
PGE1 353.2334 468.3340 
13,14-dihydro-15-keto-PGF2a 353.2334 468.3340 
6-keto-PGE1 367.2126 482.3133 
TXB2 369.2283 484.3289 
6-keto-PGF1a 369.2283 484.3289 
 
 
When the carbonyl group in the ring structure of prostanoids reacts with the GT, 
permanently charged [M+GT]+ ions are formed in the positive ion mode and with a 
mass difference of m/z 114.1029 (GT-H2O) compared to the neutral prostanoid 
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molecule. The main advantage of the derivatization with GT is the improved ionization 
efficiency as the ions are natively charged. Table 3.1 lists the prostanoid standards used 
in the research, the m/z of the [M-H]- ions (assigned by ■), and the m/z of the [M+GT]+ 
ions (assigned by *), with each isomeric prostanoid class assigned by color: red for m/z 
351/466 (■/*), green for m/z 353/468 (■/*), blue for m/z 367/482 (■/*), and purple for 
m/z 369/484 (■/*). This will be consistently used throughout the results shown. The 
mass spectra acquired after direct infusion of derivatized and nonderivatized prostanoid 
standard mixtures are shown in Figure 3.3. This figure shows the improved ionization 
efficiency from the GT derivatization when infusing equal concentration of prostanoids. 
The signal intensity is improved by a factor of >10. The m/z ratios observed in the mass 
spectrum (Figure 3.3) show the presence of multiple derivatized prostanoids. The 
[PGE2+GT]+, [PGD2+GT]+ and [13,14dihydro-15keto-PGE2+GT]+ ions were detected with 
at m/z 466.3; the [PGF2a+GT]+, [PGE1+GT]+, [PGD1+GT]+ and [13,14dihydro-15keto-
PGF2α+GT]+ ions were present at m/z 468.3. At m/z 482.3 and m/z 484.3, [6keto-
PGE1+GT]+ ions, and [TXB2+GT]+ and [6keto-PGF2α+GT]+ ions are shown, respectively. 
Unbound [GT]+ ions were observed at m/z 132.1. 
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Figure 3.3 Mass spectra of nonderivatized (a) and GT derivatized (b) prostanoid standard mixture. 
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Figure 3.4 High mass resolution MS/MS spectra acquired from individually infused GT derivatized prostanoid 
standards. The mass spectra are colour assigned consistent with other data shown in this research: PGD2, 
PGE2, 13,14-dihydro-15-keto-PGE2 in red (*), PGF2a, PGE1, PGD1, 13,14-dihydro-15-keto-PGF2a in green (*), 
6-keto-PGE1 in blue (*), and TXB2 and 6-keto-PGF1a in purple (*). 
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Furthermore, our high resolution MS/MS data confirmed the presence of GT derivatized 
TXB2 and PGF2a in standard mixture (Figure 3.4). This raises the question that the GT 
derivatization also occurs when compounds do not contain a carbonyl functional group, 
such as TXB2 and PGF2a. Although not described in literature yet, a possible explanation 
could be that TXB2 and PGF2a are occurring as a keto-enol tautomer, which has been 
described for the human serum albumin-catalyzed breakdown of 15-keto-PGE2 at pH 
4.4 to the keto-enol tautomer306, 307. A similar principle could be the case for our acid-
catalyzed GT derivatization of TXB2 and PGF2a. Even though this keto-enol tautomer 
seems to be less prone to GT derivatization than a carbonyl group, the possibility cannot 
be excluded. Brombacher et al.308 showed the derivatization of another hydrazine-like 
reagent with steroids and discussed the preference of the hydrazine nitrogen to perform 
its nucleophilic attack at the enol form of the carbonyl group rather than at the carbonyl 
group itself. The fragmentation scheme of Girard’s derivatized species has been studied 
in the past and report the formation of a 6-membered dihydropyridazinone ring and a 
5-membered dihydropyrazole ring by a neutral loss of 59 and 87, respectively309, 310. 
Structural identification of GT derivatized TXB2 is confirmed by the presence of the [M-
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Figure 3.5 High mass resolution MS/MS (a) and product ion scan (b; labelled with precursor ion scans of each 
fragment ion) of GT derivatized TXB2. The presence of the following fragment ions were observed in both 
MS/MS spectra: m/z 132.11, m/z 144.11, m/z 158.13, m/z 310.21, m/z 329.22, m/z 347.23, m/z 361.25, m/z 
365.24, m/z 379.25, m/z 397.27, and m/z 466.33. The m/z 222.01 and m/z 258.07 are not considered 
fragment ions due to their poor mass accuracy (a) and their absence in the product ion scan (b). The m/z 
425.30 is not detected in (a) but is present in (b). Structural identification of GT derivatized TXB2 is confirmed 
based on the presence of eleven fragment ions and the precursor ion (b). 
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Figure 3.6 Structural identification of GT derivatized TXB2 based on high mass resolution MS/MS. The 
presence of the following fragment ions were observed in the MS/MS spectra (Figure 3.5): m/z 132.11, m/z 
144.11, m/z 158.13, m/z 310.21, m/z 329.22, m/z 347.23, m/z 361.25, m/z 365.24, m/z 379.25, m/z 397.27, 
and m/z 466.33. The lower abundant fragment ions are depicted above (a) and the more stable fragment 
ions are depicted below (b). Structural identification of GT derivatized TXB2 is confirmed based on the 
presence of eleven fragment ions and the precursor ion. 
76
Chapter 3
147100 Lamont BNW.indd   76 21-12-2020   13:03
In summary, the direct infusion experiments confirmed the increased ionization 
efficiency when comparing derivatized prostanoids with nonderivatized prostanoids. 
This improvement in ionization is essential for further isomeric prostanoid analysis in 
the IMS comparison and detection in tissue extracts for sensitivity reasons.  
 
IMS comparison of GT derivatized prostanoid standards 
After improving the ionization efficiency of prostanoids standards by mean of 
derivatization, we compared different IMS techniques to assess the effect of this 
derivatization on the ion mobility separation of GT derivatized isomeric prostanoids. 
Figure 3.7 depicts the IMS spectra assigned by color (■/■/■/■) for m/z 466, m/z 468, 
m/z 482 and m/z 484 values, respectively. A note should be made regarding the 
different amount of passes in the cIMS experiments. Due to a so-called ‘wrap-around’ 
effect of ions, where the fastest ions catch up with the slowest ions in the cIMS loop, a 
limit number of passes could be performed for the different m/z values311. For the 
identification of the derivatized prostanoids standards, MS/MS spectra were acquired 
using high resolution MS (Figure 3.4) and compared with the fragment ions found in 
the IMS-MS analyses. Only identified peaks were labeled in the IMS spectra, based on 
infusion of individual standards followed by MS/MS fragmentation. 
 
 
Figure 3.7 High resolution IMS spectra of a GT derivatized prostanoid standard mixture: cIMS, TIMS and 
FAIMS analyses show peaks at m/z 466, m/z 468, m/z 482 and m/z 484 for multiple isomers which are labelled 
in the spectra. Identification is confirmed by MS/MS and infusion of individual standards. 
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Significant differences are observed between the three IMS, such as the number of 
detected isomers. For instance for m/z 466, 4, 5 and 10 peaks are observed in the cIMS, 
TIMS and FAIMS spectra, respectively. FAIMS spectra consistently show more and better 
separated peaks throughout the spectra. This could be explained by the fact that the 
separation in FAIMS is based on nonlinear IMS while TIMS and cIMS are based on linear 
IMS. The latter two techniques operate at low electric fields leading to a linear 
relationship between the ion’s velocity and the electric field applied. FAIMS rapidly 
switches between a low and high electric field in an asymmetric manner which results 
in a nonlinear relationship between the velocity and the electric field. Nonlinear IMS is 
much more orthogonal to mass spectrometry than linear IMS hence the improved 
separation72. Therefore, our FAIMS spectra show a much larger amount of peaks after 
infusion of the same isomeric standard mixture. Another significant difference between 
our FAIMS and TIMS/cIMS spectra is the difference in intensity due to environmental 
conditions. Both cIMS and TIMS are performed under vacuum conditions while FAIMS 
operates at atmospheric pressure. Although FAIMS provides the largest resolving power 
(partly due to atmospheric conditions), this atmospheric environment leads to a 
significant loss in ion transmission. When comparing TIMS and cIMS, minor variations 
in isomeric separation could be observed due to the ‘reversed’ mechanism of both IMS 
techniques. In cIMS, the electric field transports ions through the buffer gas while TIMS 
uses the electric field to trap ions as a carrier gas transports them through the IMS cell. 
This ‘reversed’ principle between cIMS and TIMS explaines that the ion’s path length is 
generated differently by optimizing gas velocity and time. A longer path in cIMS is 
established by more passes and, as a result, a physically longer path (50-120 ms arrival 
time). In TIMS, a longer path is accomplished by a longer trapping time (450 ms trapping 
time). The IMS separation time scale should be considered when comparing cIMS and 
TIMS. In FAIMS, this is in the range of minutes (>20 min). 
For identification of prostanoids, some of the isomeric prostanoids can be separated 
based on specific MS/MS fragment ions alone, such as PGE1/PGD1 from PGF2a. However, 
this is not possible for the separation of PGE1 from PGD1 nor of PGE2 from PGD2 using 
MS/MS alone. From a biological point of view, this isomeric separation is crucial in the 
study of the different metabolic pathways of prostanoids (e.g. COX-1 and COX-2)258. 
FAIMS is the most successful in the separation of these crucial isomeric prostanoids. In 
addition, multiple peaks for one compound are observed in almost all IMS spectra. This 
could be a result of the ability of IMS to not only separate isomers but also 
stereoisomers, in particular for FAIMS separation. This could be due to the drastic 
changes in the Khigh/Klow ratio. Literature shows that FAIMS is able to separate the 
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Figure 3.8 High resolution IMS spectra of a GT derivatized mini pig intestinal tissue extract: cIMS, TIMS and 
FAIMS analyses show peaks at m/z 468, m/z 482 and m/z 484 for multiple isomers which are labelled in the 
spectra. Identification is confirmed by MS/MS and by comparison with prostanoid standards. 
 
Prostanoids in mini pig intestine tissue extracts 
Endogenous prostanoids were investigated here in a mini pig intestine tissue extract 
using cIMS, TIMS and FAIMS to assess their detectability in biological matrices using the 
previously optimized method. Figure 3.8 shows the IMS spectra assigned by color 
(■/■/■) of m/z 468, m/z 482 and m/z 484 after direct infusion of GT derivatized mini 
pig intestine tissue extracts. Peaks were identified based on direct infusion of individual 
standards and MS/MS spectra. The aspects mentioned in the IMS comparison apply here 
more extensively. Even with the GT derivatization, one could argue that the occurrence 
of ion suppression from the sample matrix is still a point of attention. The combination 
of lower total ion transmission due to atmospheric conditions and the suppression from 
matrix ions causes a limited number of detected analyte ions after FAIMS analysis. 
However, the modification of the ion chemistry by the GT derivatization changes the 
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ionization competition occurring in the gas phase and, therefore, promotes the 
ionization of the derivatized prostanoids. This is shown in the FAIMS comparison of GT 
derivatized and nonderivatized compounds (Figure 3.9). Despite the possibility of ion 
suppression from tissue matrix and a loss in total ion transmission from FAIMS to MS, 
low-level prostanoids (5-100 ng/g tissue determined by quantitative LC-MS) were 
detected in tissue extracts. We see potential in FAIMS-MS as a powerful tool in 
combination with chromatography for isomeric separation of prostanoids.  
 
 
Figure 3.9 Comparison of derivatized and nonderivatized prostanoids in tissue extract. The mass spectrum 
of the GT derivatized tissue extract shows peaks at m/z 468.3 (*), m/z 482.3 (*), and m/z 484.3 (*). No 
prostanoid peaks are observed in the mass spectrum of the nonderivatized tissue extract. 
 
In linear IMS, the GT derivatization provides an opportunity for endogenous detection 
of prostanoids. 6k-PGE1 was detected at m/z 482 and TXB2 and 6k-PGF2a were observed 
at m/z 484. At m/z 468, different prostanoids are detected in the tissue extract after 
cIMS and TIMS. This is interesting considering that the ionization technique is the same, 
the IMS separation is identical to that applied to the prostanoid standards and the mass 
resolving power is similar. Interfering background ions from the sample matrix could 
mask the presence of prostanoids. IMS is known to decrease the level of contaminating 
background ions and could, due to the different mechanisms of both techniques, 




This work demonstrates that high resolution IMS is a very powerful approach for the 
separation and identification of prostanoids present in complex matrices like biological 
tissues. Chemical derivatization with GT reagent significantly contributed to improve 
80
Chapter 3
147100 Lamont BNW.indd   80 21-12-2020   13:03
the ionization efficiency of both standards and endogenous prostanoids, and thus 
improve sensitivity for their detection in tissue samples. The increase in signal intensity 
in the mass spectra by GT derivatization demonstrates the significant improvement in 
ionization despite the possible occurrence of ion suppression. The comparison between 
cIMS, TIMS and FAIMS revealed the strengths and weaknesses of all three IMS 
techniques in which a clear distinction is observed between linear and nonlinear IMS. 
Linear IMS provides the best sensitivity for endogenous analysis while nonlinear IMS 
delivers the highest IMS resolution. The combination of significantly improved ionization 
efficiency and isomeric separation power by high resolution IMS after GT derivatization 
confirms its applicability for low-level prostanoid analysis without the need of expensive 
and time-consuming sample clean up. Our derivatization strategy offers high sensitivity 
and excellent stereoisomeric separation for screening of complex biological systems. 
High resolution IMS, in combination with other orthogonal analytical techniques, could 
further unravel the role of isomeric prostanoids in biology and disease.  
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Mass spectrometry imaging (MSI) has proven to be a valuable tool for drug and 
metabolite imaging in pharmaceutical toxicology studies and can reveal for example 
accumulation of drug candidates in early drug development. However, the lack of 
sample cleanup and chromatographic separation can hamper the analysis due to 
isobaric interferences. Multiple reaction monitoring (MRM) uses unique precursor ion-
fragment ion transitions to add specificity which leads to higher selectivity. Here, we 
present a targeted imaging platform where desorption electrospray ionization (DESI) is 
combined with a triple quadrupole (QqQ) system to perform MRM imaging. The 
platform is applied to visualize i) lipids in mouse brain tissue sections and ii) a drug 
candidate (B) and metabolite (A) in canine liver tissue. All QqQ modes are investigated 
to show the increased detection time provided by MRM as well as the possibility to 
perform dual polarity imaging. This is very beneficial for lipid imaging since some 
phospholipid classes ionize in opposite polarity (e.g. PC/SM in positive mode and PS/PE 
in negative mode). Drug and metabolite images are obtained to show its strength in 
drug distribution studies. Multiple MRM transitions are used to confirm the local 
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4.1 Introduction 
Drug discovery and development aims to find suitable candidates that can inhibit or 
activate a pathway to have a positive effect in a disease state82. The desired effect is the 
potential drug being distributed to the target site and bound to the biological receptors 
present for a certain amount of time at a high enough concentration83. However, if a 
drug candidate, or its metabolite(s), accumulates in tissue it can result in significant 
toxicological effects. In addition, these effects can also derive from the presence of 
specific (secondary) drug metabolites. Therefore, toxicology studies are key in deciding 
whether a potential drug will be further developed141. Analytical tools are thus required 
for species identification and localization. Current imaging technologies, like 
quantitative whole-body autoradiography (Q-WBA), examine drug distribution but 
require radiolabeling and therefore cannot distinguish between possible drugs and its 
metabolites142. 
 
Mass spectrometry imaging (MSI) allows label-free drug distribution investigation 
because of its ability to map drug candidates and metabolites simultaneously80, 83, 141. 
Matrix-assisted laser desorption ionization (MALDI) is often combined with MSI due to 
its high spatial resolution, sensitivity and throughput. However, difficulties in MALDI-
MSI can arise due to inhomogeneity in matrix application and the possible interferences 
arising from matrix-related signals, especially in the absence of high mass resolving 
power. Lately, ambient liquid ionization techniques have complemented MALDI-MSI, as 
they do not require external matrices to facilitate analysis. Desorption electrospray 
ionization (DESI)117 was introduced by Cooks and co-workers and has established itself 
as the main ambient tool for MSI. DESI uses an electrospray emitter to map extracted 
molecules directly from the cryo-sectioned tissue sample. The main advantages of DESI 
are the minimal sample preparation required prior to analysis and its compatibility with 
histological staining131. DESI imaging of lipids99, 115 is the most popular but the 
pharmaceutical industry has gained interest in the technology313 for applications like 
drug blood-brain barrier permeability314 and cassette dosing155. 
 
Independent of the ionization source, constant technical improvements are made to 
improve MS detection. The integration of ion mobility spectrometry (IMS)228, 315 with 
MSI increases selectivity by reducing the interference from isobaric background 
compounds. Not only IMS but also using high mass resolution MSI316, 317 allows the 
separation of isobaric interference from targeted analytes, which is beneficial for drug 
analyses where chemical background from biological samples is a real burden. Even 
though the mass resolving capability of the newest high resolution instruments is 
significant, examples are found in literature of isobaric compounds that could not be 
separated130. In consequence, a more selective tandem MS (MS/MS) approach is 
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required to separate these isobaric compounds and are generally executed using a QqQ 
instrument. Although referred to as a triple quadrupole instrument (QqQ) by mass 
spectrometrists, most commercially available QqQ instruments nowadays only use two 
quadrupole mass analyzers and, therefore, are often called tandem quadrupole (TQ) 
instruments3. In consistency with the MS field, we refer to the system as a QqQ 
instrument318. The QqQ uses the first quadrupole (Q1), followed by a collision cell (q) 
being activated or de-activated, and second quadrupole (Q3) to either select or scan 
ions. The system can be used in different modes25, 319: MS scan (Q1 operates in RF only 
mode, no fragmentation, Q3 is scanning), product ion scan (Q1 is selecting, Q3 is 
scanning; PROD), precursor ion scan (Q1 is scanning, Q3 is selecting; PREC), neutral loss 
scan (Q1 is scanning and Q3 is scanning with an offset specific for a neutral fragment; 
NL), and multiple reaction monitoring (Q1 and Q3 are selecting; MRM). Once the 
precursor and fragment ions are known, a targeted and high-throughput MRM method 
can analyze multiple compounds simultaneously. In addition, the system enables dual 
polarity imaging in one experiment. Polarity switching has been explored previously for 
lipid MS imaging223. MALDI-QqQ imaging has also improved sensitivity for drug 
distributions studies173, 320. Other MALDI-MRM drug applications have been focused on 
skin analysis321 and forensics322, 323. MRM imaging allows for quantitative MSI 
approaches due to its wide dynamic range203.   
 
Here we report the benefits of using a QqQ mass spectrometer for targeted DESI-MS 
imaging, which is illustrated with different sets of experiments. First, the improved 
specificity of MRM is compared with the QqQ scanning modes for multiple lipid classes 
in rat brain tissue. In addition, DESI-MRM is applied to map two drug candidates (A and 
B) in canine liver. At last, lipid imaging of rat brain tissue is performed to prove the 
benefit of dual polarity imaging. 
 
4.2 Experimental section 
Materials and reagents 
ULC/MS-grade water (H2O), ULC/MS-grade methanol (MeOH), ULC/MS-grade ethanol 
and 99% formic acid (FA) were purchased from Biosolve (Valkenswaard, NL). 
Microscopic glass slides were purchased from Thermo Scientific (Braunschweig, DE). 
Drug candidate standards (compound A and B) was provided by Janssen R&D (Beerse, 
BE). 
 
Tissue collection and preparation 
Rat brain and canine liver were used in this research. MAASTRO clinic (Maastricht, NL) 
provided Wistar Albino Glaxo Rat brain tissues that were snap frozen in liquid nitrogen. 
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Janssen R&D (Beerse, BE) provided canine liver tissues dosed with a drug candidate (B) 
at 65 mg/kg. In vivo, drug B metabolizes into a dealkylated metabolite identical to the 
structure of compound A. For confidentiality reasons, structural information of the drug 
candidates cannot be revealed. All tissue samples were stored at -80 °C until cryo-
sectioning. Fresh-frozen tissues were cryo-sectioned using a Microtome cryostat 
(Thermo Scientific, Braunschweig, DE) into 12-µm thick tissue sections and thaw 




A Xevo TQ-S micro was equipped with a DESI source for the MSI analysis (Waters). DESI 
solvent (MeOH/H2O, 98/2, v/v) was supplied by a Waters ACQUITY UPLC M-class binary 
solvent manager at 2-5 µl/min. For positive ionization experiments, 0.1% FA was added 
to the DESI solvent. General parameters were: N2 nebulizing gas pressure = 3-5 bar; 
spray voltage = ±3-4 kV; MS source temperature = 150 °C;sampling cone voltage = 25 
V. A custom-built inlet capillary was heated to 300-500 °C. Pixel sizes differed per MSI 
analysis from 30-100 µm. Mass resolution settings were optimized to unit resolution. 
NL/PREC/PROD scan times ranged from 0.995-2.496 sec/pixel and MRM dwell times 
ranged from 0.199-0.999 sec/pixel. All images were acquired with Omni Spray 2-D 




Hematoxylin and eosin (H&E) staining was executed on the same tissue sections after 
DESI-QqQ analysis. The tissue sections were washed in successive EtOH baths (100%, 
96%, 70%) and deionized water for 3 min each. Hematoxylin (Merck, Darmstadt, DE) 
staining was executed for 3 min followed by a gentle 3 min wash with running tap 
water. Eosin staining is performed for 30 sec, followed by a gentle wash with running 
tap water for 3 min. The protocol was finalized by a 1 min EtOH wash and a 30 sec 
xylene wash for dehydration. Cover slips were placed on the stained tissues using 




Data processing and visualization 
For all QqQ imaging experiments, individual line scans were acquired. For individual 
MRM transitions, all raw line scan files were converted into mzML with MSConvertGUI 
(Vanderbilt University, Nashville, TN, USA) and further processed by an in-house written 
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MATLAB script (v. R2015a). To visualize NL/PREC/PROD images, raw line scan files were 
directly processed by a MATLAB script.  
 
4.3 Results and discussion 
Scanning versus MRM 
MRM mode was investigated and compared with several scanning modes to target 
multiple high and low abundant lipid classes324. First, a DESI-NL scan of 87, 
corresponding to deprotonated phosphatidylserine (PS) lipids, was performed325. This 
was followed by a DESI-MRM imaging experiment (consecutive tissue section) of 5 
corresponding MRM transitions selected from the NL spectrum (Figure 4.1a). The same 
strategy was used for the experiments in negative ion mode. In positive ion mode, a 
DESI-PREC imaging experiment was executed to scan for precursors with the m/z 184 
fragment ion324 corresponding to protonated phosphatidylcholine (PC) and 
sphingomyelin (SM) lipids. Based on the PREC spectrum (Figure 4.1b) 5 lipid species at 
variable abundance were selected. The corresponding MRM transitions were used in a 
DESI-MRM imaging experiment on a consecutive tissue section.  
 
 
Figure 4.1 NL spectrum (a) of 87 acquired from rat brain in negative ion mode. PREC spectrum (b) of m/z 
184 acquired from rat brain in positive ion mode. Corresponding images are shown in Figure 4.2. 
 
Figure 4.2 shows the resulting MS/MS images of ten lipid species of which five were 
obtained in positive ion mode (PC and SM, left 2 columns) and five in negative ion mode 
(PS, right 2 columns). Using MRM for MS imaging experiments significantly adds 
specificity to the analysis compared to MS scan. The terms specificity and selectivity are 
often confusingly used. Selectivity is the ability of a method to distinguish between the 
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analyte and its sample matrix. Specificity is the ability to measure one specific analyte in 
presence of its sample matrix (i.e. near 100% selectivity for one specific analyte)326. With 
MRM imaging, the selection of the fragment ion corresponding to the precursor ion 
adds specificity to the analyte and, therefore, measures this compound at near 100% 
selectivity. This allows separation of compounds with higher selectivity than current high 
mass resolving power MS technologies. Lanekoff et al. have combined nanospray DESI 
with multiplexed MS/MS imaging126.  
 
In this work, MRM could separate both isobaric metabolites and isobaric lipids where 
current high mass resolving power MS failed. An example is the separation of the 
[M+Na]+ ion of PE(P-16:0/22:6) at m/z 770.5095 from the [M+K]+ ion of PC 32:1 at m/z 
770.5097. The use of MRM versus PREC/NL scanning modes increases the total 
detection time per precursor ion. For instance, in NL scanning mode, [PS(44:10)-H]- is 
acquired at an acquisition rate of 20,000 Da/sec over a m/z 500-1000 mass range at a 
scan rate of 2.496 sec/pixel. This leads to a total detection time of 62.4 ms/pixel for the 
[PS(44:10)-H]- ion. In MRM mode, at the same total analysis time, the image of 
[PS(44:10)-H]- was acquired at 999 ms/pixel. This results in MRM images from low-
abundant lipid species (<1% for PS(44:10)) that are poorly detected in NL scanning 
mode. Not only is DESI-MRM imaging more selective but also significantly reduces 
analysis costs relative to high mass resolving MS imaging of isobars; which can be an 
argument for implementation in the pharmaceutical industry. 
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Figure 4.2 TIC images acquired in scanning and MRM modes. Left two columns show images acquired in 
positive mode, and the right two columns show images acquired in negative mode. In the left two columns, 
DESI-PREC images (scan time 0.995 s) are compared with DESI-MRM images (dwell time 0.199 s/MRM) of 
the same species. The right two columns show the DESI-NL images (scan time 2.496 s) and their related DESI-
MRM images (dwell time 0.999 s/MRM). Pixel size is 100 μm. H&E images are displayed at the bottom of 
each column. 
 
Confirmation of spatial localization of drug and metabolites  
Due to the additional specificity of DESI-MRM imaging, this technology is a suitable tool 
to pharmaceutical studies. The canine liver tissues used for this MRM imaging 
application are obtained from an investigation of a possible drug candidate for prostate 
cancer: Compound B with a molecular weight of 515 g/mol ([B+H]+ ion at m/z 516) 
which is metabolized into the demethylated metabolite A at 501 g/mol ([A+H]+ ion at 
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m/z 502). Based on preliminary experiments performed in Janssen R&D, a NL spectrum 
of 418 was obtained followed by a PROD spectrum of compound A. This information 
was used in the selection of two specific MRM transitions for each compound (m/z 516 
→ m/z 98, m/z 516 → m/z 488; m/z 502 → m/z 84, m/z 502 → m/z 474). To confirm 
spatial distribution, all MRM transitions are used to map the drug candidate and its 
metabolite. Figure 4.3 shows two MRM images of compound A (Figure 4.3a and 4.3b) 
and two of metabolite A (Figure 4.3c and 4.3d). All MRM images reveal significant 
accumulation of A and B in tissue lesions, which are visible in the H&E images and 
highlighted by arrows in figure 4.3e. To complement the DESI-MRM data, additional 
MALDI-MSI experiments were executed and display similar distribution of A and B 
(Figure 4.4).  
 
The accumulation of compound B correlates with histological lesions previously 
annotated by the pathologist and indicates severe fibrosis which resulted in the 
exclusion of compound B from further development. It is worth mentioning that the 
occurrence of ion suppression and/or enhancement due to the presence of bile acids in 
the bile duct may influence the detected levels of compound B201. However, qualitative 
MSI provides pharmaceutical researchers with unique understanding on drug 
distribution142. This qualitative information benefits significantly from selective MS 
detection. Our data shows that MRM imaging can not only be used for this selective 
detection of drugs and metabolites but also for spatial confirmation (e.g. accumulation 
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Figure 4.3 Spatial distribution of compounds A (a and b) and B (c and d) by two MRM transitions. H&E image 
(e) shows tissue lesions (pointed by arrows) in the canine liver. Spatial resolution is 50 µm. Dwell time/MRM 




Figure 4.4 H&E image (a), optical image (b) and MALDI-MSI images of B (c) and A (d) of same canine liver 
tissue. Tissue section were coated with 15 mg/ml DHB in 2:1 CHCl3:MeOH with 0.2% TFA using the 
SunCollect sprayer (Sunchrom GmbH, Friedrichsdorf, Germany) in a series of 15 layers. The MALDI-MSI 
images were acquired on a Bruker RapifleX MALDI Tissuetyper instrument equipped with an Nd:YAG laser 
(355 nm, 10 kHz. General MS settings were as follows: mass range = m/z 400-1000; MS mode = reflectron 
mode; ionization mode = positive ion mode; laser power = 80 % with an accumulation of 200 shots; spatial 
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Figure 4.5 Dual polarity DESI-MRM imaging performed in one experiment. In rat brain, four different DESI-
MRM images of lipids are acquired of which two in +ve mode (b and c; dwell time 0.193 sec/MRM) and two 
in –ve mode (d and e; dwell time 0.193 sec/MRM). In +ve mode, two MRM transitions target the PC head 
group while two different acyl chains are targeted in –ve mode. Spatial resolution is 100 µm. In canine liver, 
two MRM transitions target compound A and B in +ve mode (g and h; dwell time 0.485 sec/MRM) and two 
MRM transi-tions image bile acids in –ve mode (i and j; dwell time 0.498 sec/MRM) that are co-localized with 
A and B. Spatial resolution is 30 µm. H&E images of rat brain and canine liver are shown in (a and f), 
respectively. 
 
Dual polarity MS imaging 
In addition to the improved specificity, another benefit of using a QqQ mass 
spectrometer is the ability to perform fast dual polarity experiments. Figure 4.5 shows 
two applications of dual polarity MRM imaging: lipid imaging in rat brain and 
drug/metabolite imaging in canine liver. In the lipid imaging application, the images of 
four MRM transitions of which two transitions (Figure 4.5b and 4.5c) are acquired in 
positive ionization mode and two transitions (Figure 4.5d and 4.5e) are obtained in 
negative ionization mode in one experiment. Even though shown in MRM mode, the 
dual polarity capacity also applies to the scanning modes of the QqQ. This means that 
lipid classes can be evaluated based on both positive and negative charged head groups 
and/or acyl chains in one single experiment. In the pharmaceutical application, 
compound A and B are mapped (4.5g and 4.5h) in positive ionization mode and two 
bile acids are targeted (4.5i and 4.5j) in negative ionization mode. The main advantage 
of dual polarity MS imaging is that the information acquired originates from the same 
tissue section and, therefore, significantly reduces analysis time. Previous untargeted 
dual polarity MSI investigations327 using Orbitrap mass spectrometers have shown that 
polarity switching takes up to multiple seconds to reach the expected mass accuracy. 
The benefit of saving analysis time got lost because this one experiment takes twice as 
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long. Nazari and coworkers328 improved the polarity switching capability of the Orbitrap 
MS to a 96 ms switching time. Our QqQ MSI experiments have very limited elongation 
of analysis time since the polarity switching time is 15 ms. Ellis et al.223 showed the 
benefit of dual polarity lipid imaging in a classification model throughout tumor tissue 
using MALDI-MSI. The use of dual polarity MALDI imaging has the limitation that a 
MALDI matrix has to be applied, which can cause potential inferences, risks 
delocalization, and requires sample preparation time. DESI imaging does not require an 
external matrix to facilitate ionization and, therefore, does not suffer from these 
limitations. Taylor and coworkers reported the investigation of ion suppression of 
olanzapine on mouse brain where DESI ionization suffered from significantly less ion 
suppression than MALDI ionization202. Depending on the chemical structure of the drug 
candidate, this makes DESI dual polarity imaging of potentially more interest for the 
pharmaceutical industry over MALDI dual polarity imaging. In pharmaceutical sciences, 
the possibility of drugs and its metabolites ionizing in different polarities is also very 
probable. For instance, a drug that ionizes in positive mode will ionize in negative mode 
after glucuronide or sulfate conjugation329. In addition, possible endogenous markers 
for drug candidates could also ionize best in the opposite ionization mode (e.g. bile 
acids for bile duct cancer drugs). This is also shown in our drug/metabolite application 
in which two possible drug candidates and two bile acids are images and show co-
localization. The ability to map drug candidates, drug metabolites and endogenous 
metabolites in one experiment is crucial in further targeted imaging analyses and, 
therefore, DESI dual polarity imaging can play an important role. 
4.4 Conclusion 
This work demonstrates a novel targeted DESI imaging platform by using a QqQ mass 
analyzer combined with a targeted MS/MS-based data acquisition approach. The 
opportunity to perform dual polarity imaging combined with DESI is very advantageous 
for lipid and metabolite imaging since it does not rely on MALDI matrices. QqQ scanning 
modes are compared with MRM showing increased ion detection time of MRM. This 
opens doors for the separation of isobars and certain isomers which cannot be 
separated with current high mass resolving power MSI technologies. Although this 
targeted platform requires fragmentation knowledge the MSI field will significantly 
benefit from this as its applications are increasing. Our platform shows its strength in 
toxicology studies by selective imaging of drugs and metabolites in tissue. Spatial 
distribution is confirmed by monitoring the presence of pharmaceutical compounds 
using multiple MRM transitions of the same precursor ion. DESI-MRM imaging allows 
for selective imaging without the need for expensive MSI instrumentation. 
MSI can suffer from lower sensitivity compared to techniques that combine mass 
spectrometry with separation step prior to ionization137. The use of MRM in the MS 
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imaging field is very promising because improved selectivity is needed to visualize more 
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Mass spectrometry imaging (MSI) provides insight in the molecular distribution of a 
broad range of compounds and, therefore, is frequently applied in the pharmaceutical 
industry. Pharmacokinetic and toxicological studies deploy MSI to localize potential 
drugs and their metabolites in biological tissues but currently require other analytical 
tools to quantify these pharmaceutical compounds in the same tissues. Quantitative 
mass spectrometry imaging (Q-MSI) is a field with challenges due to the high biological 
variability in samples combined with the limited sample cleanup and separation 
strategies available prior to MSI. In consequence, more selectivity in MSI instruments is 
required. This can be provided by multiple reaction monitoring (MRM) which uses 
specific precursor ion-fragment ion transitions. This targeted approach is in particular 
suitable for pharmaceutical compounds because their molecular identity is known prior 
to analysis. In this work, we compared different analytical platforms to assess the 
performance of MRM detection compared to other MS instruments/MS modes used in 
a Q-MSI workflow for two drug candidates (A and B). Limit of detection (LOD), linearity, 
and precision and accuracy of two quality control (QC) samples were compared 
between MS instruments/modes. MRM mode on a triple quadrupole mass spectrometer 
(QqQ) provided the best overall performance with the following results for compound 
A and B: LOD 35.5 and 2.5 µg/g tissue, R2 0.97 and 0.98 linearity, relative standard 
deviation QC <13.6%, and 97-112% accuracy. Other MS modes resulted in LOD 6.7-
569.4 and 2.6-119.1 µg/g tissue, R2 0.86-0.98 and 0.86-0.98 linearity, relative standard 
deviation QC < 19.4 and <37.5%, and 70-356% and 64-398% accuracy for drug 
candidate A and B, respectively. In addition, we propose an optimized 3D printed 
mimetic tissue model to increase the overall analytical throughput of our approach for 
large animal studies. The MRM imaging platform was applied as proof-of-principle for 
quantitative detection of drug candidates A and B in four dog livers and compared to 
LC-MS. The Q-MSI concentrations differed <3.5 times with the concentrations observed 
by LC-MS. Our presented MRM based Q-MSI approach provides a more robust and high 
throughput analytical platform due to MRM specificity combined with an optimized 3D 
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5.1 Introduction 
Mass spectrometry imaging (MSI) has proven to be an invaluable tool for the 
pharmaceutical industry to directly localize drugs and related metabolites from tissue 
specimens83, 142. In the field of drug discovery and development, MSI has been applied 
in (amongst others) pharmacokinetic and toxicological studies to investigate whether a 
drug and/or metabolite accumulate in tissue. This potentially toxicological accumulation 
could lead to exclusion of a compound from the drug development pipeline141. 
Therefore, it is of utmost importance to spatially quantify the accumulation of a possible 
drug candidate and its metabolites. The ability to provide reliable absolute quantitative 
information is challenged by numerous factors. These include the lack of sample 
cleanup or chromatography and, as a result, occurrence of tissue ion suppression and 
interference of isobaric species in complex biological samples137, 245.  
Quantitative MSI (Q-MSI) has been a field of discussion in the past decade142, 201, 330. 
Researchers have investigated several approaches331-333 to improve Q-MSI 
performance204, 208.  Three common strategies have been applied for the addition of the 
calibration standards: i) the tissue extinction coefficient (TEC) model208, ii) the dilution 
series model196, and iii) the mimetic tissue model206. The TEC approach uses the drug 
standard (‘pseudo’ internal standard) sprayed onto a control tissue section. The TEC is 
a regional correction factor calculated by the intensity of the standard on tissue divided 
by the intensity of the standard on the glass slide. The TEC can be calculated for 
different regions within the tissue sample. The sample preparation is quick but the 
approach lacks the ability to correct for tissue ion suppression and extraction efficiency. 
The dilution series strategy uses calibration standards spotted onto or below a control 
tissue section. This way the ion suppression effects are better mimicked but the 
correction for extraction efficiency is still limited. Recently, the mimetic tissue model 
was introduced by Groseclose and coworkers206 and uses tissue homogenates spiked 
with calibration standards to quantify targeted compounds in the tissue section. Even 
though it requires more sample preparation, this strategy closely resembles the drug 
‘in-tissue’. Hansen et al.334 and Barry et al.207 have both compared the mimetic tissue 
model and the dilution series model. Much lower absolute intensities and a lower slope 
value suggest that the mimetic tissue model experiences more tissue ion suppression. 
As a result, the mimetic tissue model appropriately corrects tissue specific ion 
suppression effects and extraction efficiencies better than in the dilution series 
approach. Barry et al. recently reported a revised mimetic tissue model207 to overcome 
the time-consuming sample preparation. A quantitative assessment of its performance 
demonstrated the benefit of their approach335, 336. Nevertheless, this approach risks 
cross-contamination amongst calibration levels when the frozen tissue homogenate are 
removed from the mold. Majority of reported research uses an isotope-labelled standard 
for correction as the occurrence of tissue ion suppression is not only tissue/organ-
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specific but also analyte-specific. However, isotope-labelled analogues are rarely 
available for drug candidates under development or are extremely expensive to obtain.  
Several strategies and instruments are available for MSI to overcome the challenge of 
ion suppression due to the lack of sample cleanup. Derivatization strategies110 and 
washing steps, to remove competing sample matrix molecules,337 can be applied 
complementary to the use of an internal standard (if available). When limited sample 
preparation strategies are applicable, isobaric interferences can mask the detection of 
the analyte. High selectivity can separate these isobaric interferences in complex 
biological samples. This could be achieved through the use of ion mobility separation100 
or high resolving power mass spectrometry combined with imaging317. Targeted MSI 
has also shown advantages for isobaric separation from biological tissue samples203, 320.  
For example, multiple reaction monitoring (MRM) combined with MSI showed promise 
in several applications in drug distribution studies323, 338 and endogenous metabolites126. 
Although the use of MRM is already standard practice in the pharmaceutical industry 
for decades, this is not the case for pharmaceutical MSI. The main advantages of MRM 
imaging are the high throughput and specific screening of multiple known analytes and 
a high dynamic range of the instrument339. The improved specificity (i.e. near 100% 
selectivity for one specific analyte) of MRM imaging decreases the interference of 
background ions and leads to an improved signal-to-noise. This feature of MRM 
imaging could lead to enhanced performance of Q-MSI. We recently introduced a 
targeted imaging approach through a combination of MRM with desorption 
electrospray ionization (DESI) imaging340. Although the Q-MSI discussion mainly focuses 
on MALDI imaging, DESI has established itself as the main ambient ionization source 
for MSI130. DESI uses an electrospray jet to extract and map molecules directly from 
tissue sections117. Unlike MALDI imaging, DESI does not suffer from the signal variation 
caused by the application of a MALDI matrix prior to MSI analysis. The pharmaceutical 
industry showed increased interest in DESI imaging313 for multiple applications144, 176, 186, 
314. A targeted MRM imaging platform could be of great interest for the pharmaceutical 
industry since the analyte of interest is known prior to analysis and reduces the analysis 
costs compared to high mass resolving power MSI. We investigate the potential of MRM 
imaging for quantitative drug imaging in the context of the pharmaceutical demand for 
Q-MSI technology.  
Here, we evaluate different platforms to improve selectivity and sensitivity of Q-MSI. 
We established a multiplatform comparison among different MS detection modes and 
instruments, followed by a Q-MSI application of two drug candidates in dog liver. First, 
a mimetic tissue model was adapted to investigate the sensitivity of different platforms 
using two drug candidates. These samples were analyzed on three different Waters 
mass spectrometers compatible with the same DESI source and using the same control 
software: two quadrupole time-of-flight (Q-TOF) instruments (Synapt G2-Si and Xevo 
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G2-XS) and a tandem quadrupole or triple quadrupole (QqQ) instrument (Xevo TQ-S 
micro), consisting of two quadrupoles and a nonquadrupolar collision cell3. We 
hypothesize that the QqQ has the best analytical performance in MRM mode due to 
the additional specificity. Limits of detection (LOD), linearity, accuracy and precision 
from low and high concentrations of quality control (QC) samples were calculated for 
two drug candidates, to compare the performances of the different platforms and 
analysis modes. As a proof-of-principle, the mass spectrometer with the best analytical 
performance was used to map and quantify both drug candidates in dog liver tissues. 
Quantitative DESI-MSI results were compared to drug levels measured by LC-MS analysis 
of the same samples. 
 
5.2 Experimental 
Materials and Reagents 
ULC/MS-grade water (H2O), ULC/MS-grade methanol (MeOH), LC/MS-grade ethanol 
(EtOH), LC/MS-grade xylene, and 99% formic acid (FA) were obtained from Biosolve 
(Valkenswaard, NL). Gelatin was purchased from Sigma-Aldrich. Microscope glass slides 
were obtained from Thermo Scientific (Braunschweig, DE).  
 
Mimetic tissue model preparation and multiplatform comparison setup 
A mold was printed from VeroWhitePlus RGD835 (Stratasys, DE) using a 3D Objet30 
Prime printer (Stratasys, DE). The inside of the mold was covered with a thin layer of 
clear nail polish (Hema, NL) to prevent adhesion by gelatin. A warm 15% gelatin 
solution was pipetted into the mold and cooled on ice for 30 min to set. In the 
multiplatform comparison, chicken liver (Plus supermarket, Maastricht, NL) 
homogenates were prepared by a mini-bead beater and 1.0 mm glass beads from 
BioSpec Products (Bartlesville, OK, USA). Chicken liver tissue was used due to the large 
amount of tissue necessary in the multiplatform comparison. Two drug candidates A 
and B (Janssen R&D, Beerse, BE) were dissolved in H2O and 5 µl were added to 100 mg 
of the chicken liver prior to homogenization. Final concentrations ranged from 12.5 to 
2500 µg/g (C1-C7 calibration levels) tissue. The gelatin block was filled with spiked 
tissue homogenates in a randomized order to prevent leverage, frozen at -20°C and 
cryosectioned onto glass slides. Glass slides were stored at -80 °C until DESI-MSI 
analysis. Calibration lines and quality control (QC) samples at 25 and 1250 µg/g level 
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Absolute quantitation in dog liver 
Animal studies were conducted in accordance with all institutional and national 
guidelines for the care and use of laboratory animals. Control and dosed dog liver 
tissues (Beagle) were obtained from Janssen R&D (Beerse, BE). Two drug candidates (A 
and B) were individually dosed at 65 mg/kg and drug candidate A was also dosed at 15 
mg/kg via single oral administration. In total, four dogs were included in this proof-of-
concept experiment: two animals were dosed 65 mg/kg drug candidate B (dog 1 and 
2; n=2), one animal was dosed 65 mg/kg drug candidate A (n=1), and one animal was 
dosed 15 mg/kg drug candidate A (n=1). All animals were sacrificed 14 days post dose. 
In vivo, drug B metabolizes into a demethylated metabolite identical to the structure of 
compound A. Partial molecular structures of both drug candidates as well as their most-
likely fragment ion, formed upon collisional activation of the protonated precursor ion, 
used in MRM is shown in Figure 5.1. This research presents an optimized MRM based 
Q-MSI approach compared to other MS modes and complemented with an MRM based 
proof-of-principle application. Since this research is not a biological investigation of the 
drug candidates but a technological comparison for Q-MSI, we believe full structural 
information is not required and, for confidentiality reasons, only the relevant structure 
is included. A calibration line and quality control (QC) samples (n=3) with drug 
candidate A and B were prepared in control dog liver using the mimetic tissue model 
previously described. Fresh-frozen tissues and gelatin block were stored at -80 °C until 
cryosectioning. A Microtome cryostat (Thermo Scientific, Braunschweig, DE) was used 
to cryosection liver tissue and the gelatin block into 12 µm-thick slices and subsequently 
thaw mounted the sections onto microscope glass slides. All glass slides were stored at 




147100 Lamont BNW.indd   102 21-12-2020   13:03
 
Figure 5.1. Partial molecular structures of drug candidate A and B at, respectively, 501 g/mol and 515 g/mol. 
Two most-likely fragment ions that are used in the MRM transitions are shown at m/z 98 and m/z 84. 
 
Hematoxylin and Eosin (H&E) staining protocol 
Tissue slices used for DESI-MSI analysis were stained after completion of the MSI 
acquisition using a standard H&E staining protocol. Sections were washed in successive 
EtOH baths (100%, 96%, 96%, 70%, 70%) and deionized H2O for 3 min each.  
Hematoxylin (Merck, Darmstadt, DE) staining was performed for 3 min followed by a 
gentle 3 min wash with running tap water. Eosin (Avantor Performance Materials B.V., 
Arnhem, NL) staining was executed for 30 s and washed gently with running tap water 
for 3 min. The staining was finalized by an EtOH wash for 1 min and a xylene wash for 
30 s. The slides were covered by placing coverslips on the stained tissues using Entellan 
(Merck, Darmstadt, DE). Optical images were acquired using a VENTANA iScan HT 
scanner (Roche Diagnostics, Indianapolis, IN, USA). 
 
DESI-MSI instrumentation 
DESI-MSI analysis was performed using a DESI source (Waters, Wilmslow, UK) mounted 
onto three different Waters mass spectrometers: Xevo G2-XS Q-TOF, Synapt G2-Si Q-
TOF, and Xevo TQ-S micro QqQ. DESI solvent (MeOH/H2O/FA, 98/2/0.1) was supplied 
to the DESI source by a Waters ACQUITY UPLC M-class binary solvent manager at 2 
µL/min. General DESI parameters were: N2 nebulizing gas pressure = 4 bar; spray voltage 
= 3-4 kV; Source temperature = 150 °C; sampling cone voltage = 70 V; Heated custom-
built inlet capillary = 500 °C. All experiments were executed in positive ionization mode. 
The multiplatform comparison was performed at a pixel size of 100 µm and the 
quantitative drug application was executed at 50 µm. Different MS modes were used 
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in the sensitivity comparison: MS scan (all mass spectrometers), ion mobility 
spectrometry (IMS)-MS and IMS-MSE (Synapt Q-TOF without and with data independent 
acquisition, respectively), and MRM (Xevo QqQ). All Q-TOF experiments were 
performed in sensitivity mode. Total scan times were kept constant at 0.986 s/pixel. 
MRM dwell times were set to 0.247 s/pixel with in total 3 MRM transitions per 
acquisition: m/z 502 → m/z 84 (compound A; CE 40V), m/z 516 → m/z 98 (compound 
B; CE 40V), m/z 782 → m/z 184 (endogenous lipid; CE 30V). All MS images were 
acquired using HDI Imaging (Waters, Milford, MA, USA), MassLynx version 4.1 (Waters, 
Milford, MA, USA), and Omni Spray 2-D version 2.0.1 (Prosolia, Indianapolis, IN, USA). 
 
Data processing and visualization 
HDI Imaging software (Waters, Wilmslow, UK) was used for visualization of MS images 
acquired on Xevo Q-TOF and Synapt Q-TOF and select regions of interest (ROI). We 
used an in-house written Matlab script (Matlab v. R2015a, MathWorks, Natick, MA, US) 
for data visualization and ROI selection of the MRM and MS scan data images acquired 
on the Xevo QqQ. Due to the absence of an isotope-labelled analog of the drug 
candidates, a homogeneously distributed endogenous lipid (m/z 782.6) was used to 
correct for tissue matrix effects. From each ROI, the extracted MS spectra were summed 
and different peak ratios (analyte-to-lipid) were calculated to build the calibration lines. 
QuPath software (v0.1.2, The Queen's University of Belfast, Northern Ireland) was used 
to select the ROIs from the H&E images and calculate the amount of cells present in the 
ROI. The H&E images were overlaid with the MSI images by an in-house developed 
Matlab script and overlapping pixels were extracted. The drug candidate/lipid ratio was 
calculated after correction for the number of cells detected in the ROI. This workflow 
can be found in the Figure 5.290. All calibration lines are constructed according to 
Eurachem guidelines341. When a calibration standard concentration was <LOD, this 
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Figure 5.2 Data analysis workflow consists of a 5-step procedure. Step 1: MSI and H&E images are acquired. 
Step 2: ROI selection in QuPath. Step 3: Cell analysis in QuPath to detect cells. Step 4: Overlay H&E image 
(with detected cells marked) and MSI image in an in-house written Matlab script. Step 5: MSI pixel selection 
and extraction in in-house written Matlab script. From these MS spectra, intensity ratios between the drug 
candidates and endogenous lipid are used. 
5.3 Results and discussion 
Optimization of mimetic tissue model 
The ‘in-tissue’ approach requires a very laborious process due to the homogenization 
step342. Here, we optimized the sample preparation protocol of a mimetic tissue model 
for high throughput Q-MSI purposes by designing a 3D printed mold (Figure 5.3), used 
to prepare a gelatin block with a tissue mimetic array.  
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Figure 5.3 Overview of the mimetic tissue model. Presentation of the 3D printed mold with two sets 
of screws and 15 pillars in the lid (a). Prepared gelatin block after hardening on ice (b). The gelatin 
block filled with spiked tissue homogenate (c and d) before storage at -80C. 
 
This 3D printed mold (Figure 5.3a) was designed with a lid containing 15 squared pillars 
with 3 x 3 x 8 mm dimensions (L x W x H) screwed onto the outer walls of the mold. A 
warm 15% gelatin solution was pipetted into the mold. Gelatin is often used for tissue 
embedding to assist in cryosectioning fragile or small tissues and is demonstrated to not 
interfere in the mass spectrum (unlike OCT embedding)343, 344. After the gelatin was 
hardened on ice, the two other screws were used to gently remove the lid from the 
gelatin block. The distance between the pillars of the mold was set at 2 mm to prevent 
cross-contamination between pillars due to diffusion of molecules from the tissue 
homogenate into the gelatin. This diffusion was investigated for both drug candidates 
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Figure 5.4 Diffusion of drug candidates into gelatin is shown by DESI-MRM images of a tissue 
homogenate pillar for drug candidate A, drug candidate B, and the endogenous lipid (used as a 
correction factor). The MRM images were acquired in positive ion mode at a spatial resolution of 50 
µm. Dwell times were 0.247 s/pixel. 
 
We noticed minimal diffusion and no cross-contamination of the drug candidates and 
endogenous lipid. The total dimension of the gelatin block was of 20 x 20 mm2 (L x W; 
Figure 5.3b and 5.3c) to fit on a microscope glass slide and to use the additional space 
for the sample tissue section. The 15 pillars were arranged with one empty corner to 
keep the orientation clear, which is important after addition of different tissue 
concentration levels. The volume of the spiked calibration standard was kept 5% (w/w) 
of the total tissue weight to limit the change in tissue density. The highly viscous tissue 
homogenate was aspirated using a disposable syringe to avoid air bubbles in the 
homogenates and dispensed into the empty pillar using both the syringe and a needle, 
which resulted in a filled gelatin block (Figure 5.3d). The design of our mimetic tissue 
model allows for high throughput application due to the large amount of sections that 
can be obtained from one gelatin block. This is of particular interest for the 
pharmaceutical industry when performing large scale drug studies. Figure 5.5 shows 
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Figure 5.5 H&E stained images from liver tissue (a) and liver tissue homogenates (b). MRM images 
of m/z 782 are shown from liver tissue (c) and liver tissue homogenates (d). Pixel-to-pixel variation of 
m/z 782 in liver tissue (c) and liver tissue homogenates (d) is <21% RSD and <24% RSD for n=30 
pixels, respectively. 
 
The morphology of the tissue was lost due to the homogenization step. The addition 
of 5% of solution containing the spiked standard and the homogenization process itself 
disrupted the cells, which leaded to a lower density of intact cells and nuclei. These 
tissue homogenates were used to mimic the sample tissue and, therefore, simulate an 
average tissue ion suppression (derived from endogenous cellular compounds) as occurs 
in actual liver tissue sections334, 345. In addition, we compared the distribution of the 
endogenous lipid (m/z 782) before (Figure 5.5c) and after (Figure 5.5d) homogenization 
and we confirm that in both cases the lipid intensity and distribution are similar despite 
cellular disruption caused by the mechanical homogenization process. A mimetic tissue 
model is challenging to cryosection due to the fragility of frozen tissue homogenate. 
Inhomogeneity in the cryosectioned calibration line is corrected for by the use of the 
endogenous lipid unlike other approaches that use a sprayed isotope-labelled standard 
on top of the mimetic tissue model. 
 
Multiplatform comparison 
The comparison of different mass spectrometers for DESI-MSI of both drug candidates 
in tissue is shown in Table 5.1. For each of the MS modes, the limit of detection (LOD), 
linearity (R2), QC precision (RSD), and QC accuracy (%) are reported for drug candidates 
A and B. In this paragraph, the results obtained in the multiplatform comparison are 
compared to the guideline for bioanalytical method validation as defined by the 
European Medicine Agency (EMA)346. While these guidelines are set for 
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chromatographic analytical tools applied in toxicological studies, most validation 
parameter guidelines are equally applicable to Q-MSI data. The EMA guidelines are used 
as a point of reference for Q-MSI data and not as a full validation protocol in the 
multiplatform comparison. 
 
Table 5.1 Multiplatform comparison of drug candidate A and B 
    Drug candidate A (n=3) Drug candidate B (n=3) 
MS 







Precision      
(% RSD at 
25*/1250 
µg/g) 










Precision      
(% RSD at 
25*/1250 
µg/g) 




    
        
Xevo Q-TOF MS scan 6.7 0.98 3.8/17.8 356/139 2.6 0.98 2.1/18.3 398/100 
    
        
Synapt Q-
TOF 
MS scan 36.4 0.92 <LOD/16.5 <LOD/146 4.8 0.90 1.3/16.2 167/115 
  HDMS 225.3 0.90 <LOD/17.0 <LOD/103 8.0 0.94 0.1/15.3 621/64 
  HDMSE 307.3 0.86 <LOD/19.4 <LOD/199 29.7 0.86 <LOD/20.2 <LOD/203 
    
        
Xevo QqQ MS scan 569.4 0.93 <LOD/17.7 <LOD/70 119.1 0.95 <LOD/37.5 <LOD/73 
  MRM** 35.5 0.97 <LOD/2.5 <LOD/97 2.5 0.98 8.1/13.6 100/112 
*Note that for most of the MS modes, the QC at 25 µg/g level is below LOD. 
**The best instrument/mode is highlighted in green. 
 
Sensitivity. After MSI acquisition of the calibration lines in triplicate, LOD values347 were 
calculated by multiplying the standard deviation (SD) of the blank intensity ratios 
obtained by 3. This intensity ratio was calculated into LOD concentration levels in µg/g 
tissue by using the slope of the calibration line: 
 
     ⁄  ∗ 3  
 
The Xevo Q-TOF is a very fast and sensitive instrument and frequently used in 
combination with DESI in MS scan mode. When comparing the LOD values with those 
obtained in the three scanning modes on the Synapt Q-TOF, the MS scan on the Xevo 
Q-TOF is the most sensitive scanning mode for both drug candidates. We investigated 
all three scanning modes available on the Synapt Q-TOF and all modes showed similar 
trend for both compounds with MS scan mode being the most sensitive. The application 
of ion mobility separation is known to improve selectivity due to collisions between the 
ions and gas molecules and, therefore, eliminates more background ions than analyte 
ions and enhance S/N ratios55. However, due to these ion-neutral collisions, total ion 
transmission decreases significantly348. For our two drug candidates, we conclude that 
IMS-MSE is the least sensitive mode on the Synapt Q-TOF. MS scan mode on the Xevo 
QqQ gave high LOD value for compound A and B. The LOD values reported a strong 
sensitivity gain in MRM mode: 50-fold for compound B and a mere 20-fold for 
compound A. Compound A was imaged most sensitive in MS scan mode on the Xevo 
109
MRM based Quantitative Mass Spectrometry Imaging
147100 Lamont BNW.indd   109 21-12-2020   13:03
Q-TOF. In summary, distinct specificity enhancement was obtained for compound B in 
MRM mode versus MS scanning modes. This sensitivity gain by using MRM mode seems 
to be much larger for compound B than for compound A. The explanation for a poorer 
sensitivity for compound A in MRM mode versus compound B in MRM mode could be 
a result of different fragmentation efficiencies. During optimization of the MRM 
transition, one is always searching for the most abundant fragment ion. However, this 
is not always a guarantee for the best S/N ratio for this transition. Therefore, the most 
abundant fragment ion may not provide the same sensitivity for both compounds. In 
other words, if the selectivity gain (a higher S/N ratio due to the observed background) 
of the MRM transition for compound B (m/z 98) is significantly higher than the S/N of 
the MRM transition for compound A (m/z 84), then this will result in different detection 
limits.  
Linearity. For both compounds A and B, the best linearity was observed on the Xevo Q-
TOF in MS scan mode (R2 >0.98, table 5.1). The significantly poorer correlation was 
obtained on the Synapt Q-TOF in all modes (R2 0.86-0.94). On the Xevo QqQ, the 
correlation coefficient was poor in MS scan mode (R2 0.93) and improved in MRM mode 
(R2 0.97) for compound A. For compound B, linearity values acquired on the Xevo QqQ 
(R2 >0.95) report improvement compared to the Synapt Q-TOF and is comparable to 
the Xevo Q-TOF. Variability in calibration lines could be limited by including more levels 
per calibration line, for example ≥10 calibration levels (instead of ≥7 levels for 
chromatographic approaches).  
Precision and accuracy. Spiked QC samples were included in triplicate in the 
experimental setup to investigate the performance of our Q-MSI workflow. QC samples 
were prepared at two concentration levels, i.e. 25 and 1250 µg/g tissue. Precision was 
calculated by relative standard deviations (RSD) based on n=3 replicates. For some MS 
modes, the QC samples at 25 µg/g were below the observed LOD values and not 
reported in Table 5.1. Precision should be ±15% (±20% below lower limit of 
quantification (LLOQ); defined as SDblank * 5 / slope) according to the EMA346. When we 
compare the precision levels obtained from the different MS modes, the MRM mode is 
the only MS mode that meets the EMA requirements for both drug candidates. With 
regards to accuracy, EMA guidelines at analyte concentrations ≥0.1 µg/g is -20% to 
+10%346. In our multiplatform comparison, no MS mode meets the EMA guidelines for 
both drug candidates, however, MRM mode is the closest in analytical performance to 
the EMA standard. The applicability of EMA guidelines to Q-MSI data is debatable due 
to the higher variability in Q-MSI approaches than in chromatographic strategies, which 
include the use of internal standards. More QC replicates in the Q-MSI experimental 
design could be considered to meet EMA guidelines, for example n≥5, instead of n=3 
as used in our experiments.  
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Overall, one could argue that compound B showed a significantly lower LOD value than 
compound A in MRM mode. The sensitivity might be better in MS scan mode (Xevo Q-
TOF), however, the linearity and the precision and accuracy of high and low QC samples 
show the best analytical performance in MRM imaging mode compared to all MS 
scanning modes for both drug candidates. Therefore, we selected the MRM imaging 
mode for quantitative analysis of the drugs in dog liver samples. 
 
Absolute quantitation of drug candidate compounds in dog livers 
Q-MSI based on our optimized mimetic tissue model allows for high throughput 
screening in drug studies that comprise multiple animals at multiple time points. We 
demonstrate this Q-MSI drug application as a proof-of-concept based on four different 
dog liver samples. These samples were obtained from a drug development study of two 
possible drug candidates (compound A and B) and were analyzed with DESI-MRM. Dogs 
1 and 2 are dosed 65 mg/kg B, dog 3 is dosed 65 mg/kg A, and dog 4 is dosed 15 
mg/kg A for this experiment.   
 
 
Figure 5.6 DESI-MRM images obtained from livers of dog 1 and 2 (dosed with drug candidate B at 
65 mg/kg). For dog liver 1, dealkylated metabolite image (a and b) and drug candidate B (c and d). 
Corresponding H&E images (e and f) show the tissue lesion and define the three selected ROIs. In 
addition for dog liver 2, dealkylated metabolite image (g and h) and drug candidate B (i and j). 
Corresponding H&E images (k and l) show the tissue lesion and define the three selected ROIs. 
 
DESI-MSI imaging of dog liver samples. Figure 5.6 displays the DESI-MRM image data 
obtained from sections of dog liver 1 and 2 for compound B (Figure 5.6c and 5.6i). In 
both dog liver sections, an accumulation of compound B in the bile duct (zoom in Figure 
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5.6d and 5.6j) was noticed. The dealkylated metabolite (compound A), also detected in 
dog liver 1 and 2 (Figure 5.6a and 5.6g), showed the same accumulation location (zoom 
in Figure 5.6b and 5.6h) as drug candidate B. A detailed examination by an experienced 
pathologist of the H&E stained tissue sections showed that both drug candidates caused 
histological lesions in the dog livers (Figure 5.6e and 5.6f for dog liver 1; and Figure 
5.6k and 5.6l for dog liver 2). Figure 5.7 presents the MRM compound images obtained 
from dog liver 3 (Figure 5.7a and 5.7b) and dog liver 4 (Figure 5.7e and 5.7f) for drug 
candidate A. The MRM images of the distribution of compound A in dog liver 3 and 4, 
where the actual compound A is directly dosed to the dogs, did not show the same 
accumulative pattern in “hot-spots” as occurred in dog liver 1 and 2. Q-MSI data is 
necessary to explain this observational difference between the two sets of dog livers.   
 
 
Figure 5.7 DESI-MRM images obtained from dog livers 3 and 4 of which the animals were dosed 
drug candidate A at 65 mg/kg and 15 mg/kg, respectively. For dog liver 3, drug candidate images (a 
and b) are shown. Corresponding H&E images (c and d) show the tissue lesion and define the three 
selected ROIs. For dog liver 4, drug candidate images (e and f) are shown. Corresponding H&E images 
(g and h) show the tissue lesion and define the three selected ROIs. 
 
From pixels to Q-MSI. For the quantitative calculations in the different dog livers, three 
different regions were highlighted (Figure 5.6f, 5.6l, 5.7d and 5.7h) and corresponding 
spectra extracted from the MSI data: ROI 1) tissue lesions in the bile duct and bile duct 
wall; ROI 2) the connective tissue with part of the blood vessel; ROI 3) the liver 
parenchyma349. In each dog liver tissue, ROI 1, ROI 2 and ROI 3 were extracted in 
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Figure 5.8 ROI selection in four dog liver tissues in their H&E images (Qupath software). For each 
dog liver tissue, the tissue is annotated by a pathologist and classified as tissue lesion (TL), connective 
tissue (C), and parenchyma (P). Where possible for each dog liver, ROIs of all tissue types are extracted 
in triplicate (f.e. TL1, TL2, and TL3). These H&E images were overlaid with the MSI images as described 
in Figure 5.1. 
 
Some of these extracted ROIs were marked in the H&E images in Figures 5.6f, 5.6l, 5.7d 
and 5.7h for dog livers 1, 2, 3, and 4, respectively. Tissue ion suppression correction is 
necessary for more accurate quantitative results202. Due to the absence of an isotope-
labelled analog of the drug candidates, an endogenous lipid (m/z 782) was used as 
correction factor. The endogenous lipid used for correction is homogeneously 
distributed throughout the tissue homogenates but not throughout the dog liver and, 
therefore, is not an ideal correction factor. The extraction of pixels that exclusively 
contain this endogenous lipid was guided by the regional cell count in the dog liver90. 
This workflow is shown in Figure 5.2.  
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Figure 5.9 Calibration curves (n=2) of drug candidate A (blue) and B (red) in control dog liver that 
were used to quantify the three ROIs in the four dog liver tissues. A separate plot depicts the lower 
range of the calibration curves. Error bars shows the standard deviation of the intensity ratios for each 
calibration level. 
 
Figure 5.9 depicts the calibration line for both drug candidates to obtain the 
quantitative results in the three ROIs. These calibration lines were constructed in control 
dog liver with the same linear range as used in the multiplatform comparison (12.5-
2500 µg/g) which include the targeted concentration range. With correlation 
coefficients R2>0.95, linear calibration lines were constructed and used for 
quantification of the three ROIs. For drug candidate A, precision levels of QC samples 
(n=3) were 11% at 25 µg/g and 14% at 1250 µg/g and the accuracy was determined 
at 91% at 25 µg/g and 94% at 1250 µg/g. For drug candidate B, the calculated 
precision was 12% at 25 µg/g and 12% at 1250 µg/g. Accuracy was established 94% 
at 25 µg/g and 93% at 1250 µg/g. The final absolute concentrations quantified in the 












147100 Lamont BNW.indd   114 21-12-2020   13:03






Tissue lesion Connective tissue Liver parenchyma 
Dog liver 1  
(65 mg/kg dosed B) 
A 526 ± 156 79 ± 27 242 ± 59 
B 316 ± 115 172 ± 71 495 ± 78 
  
    
Dog liver 2  
(65 mg/kg dosed B) 
A 588 ± 126 136 ± 98 577 ± 227 
B 100 ± 21 58 ± 84 269 ± 103 
  
    
Dog liver 3  
(65 mg/kg dosed A) 
A 2549 ± 673 2302 ± 966 >ULOQ 
B ND ND ND 
  
    
Dog liver 4  
(15 mg/kg dosed A) 
A 465 (n=1) 366 ± 28 (n=2) 480 ± 50 
B ND ND ND 
 
In line with the observations from the MRM images, the ‘hot spot’ (e.g. tissue lesion) 
showed a significantly higher concentration for compound A (metabolite) than in the 
connective tissue/blood vessel (6.6 times higher) and liver parenchyma (2.2 times higher) 
for dog liver 1. However, this was not the case for dog liver 2 where tissue lesions and 
liver parenchyma resulted in similar concentrations (lesion 1.02 times higher than 
parenchyma). Considering that compound A is metabolized from drug candidate B, the 
concentrations observed in the tissue lesions are lower than in liver parenchyma for dog 
liver 1 (1.6 times lower) and dog liver 2 (2.7 times lower). It is clear from the data that 
for both dog liver 1 and 2, connective tissue/blood vessel resulted in significantly lower 
concentrations. Considering that dog liver 1 and 2 are biological replicates, a similar 
trend was observed amongst the three ROIs. A clear difference was observed in the 
metabolism of the dogs, in which dog 2 metabolized more of the drug candidate (B) 
into its metabolite (A) than dog 1. The connective tissue/blood vessel and liver 
parenchyma particularly showed a higher metabolic rate, which confirms the need for 
multiple animals in large-scale drug studies. The absolute concentration levels of dog 
liver 3 and 4 showed a factor difference of >5 for tissue lesion (2549 and 465, 
respectively; factor 5.5)  and connective tissue/blood vessel (2302 and 366, respectively; 
6.3)  which can potentially be explained by the dosage difference between dog liver 3 
and 4 (factor 4.3). The observation that dog liver 3 and 4 showed minimal ‘hot spots’ 
of compound A in the MRM images is confirmed by the quantitative MSI data. All three 
ROIs yielded similar concentrations. In addition, the differences in absolute 
concentrations detected in the different tissue regions stresses the need for spatial 
quantitative information that can explain the distribution of drugs and their metabolites 
in toxicological studies. Regional laser capture microdissection of tissue followed by LC-
MS can provide absolute quantification in tissue but is an extremely laborious approach 
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when performed on multiple animals at different time points350, 351. Using our mimetic 
tissue model allows spatial quantitative screening of drugs and metabolites in large-
scale toxicology studies without being too time consuming.   
LC-MS comparison. The use of four dog livers from this pharmaceutical study allowed 
us to compare quantitative DESI-MRM data with earlier obtained LC-MS data. The 
comparison of Q-MSI data with LC-MS data of the same tissue is challenging because 
of lacking spatial information from the tissue homogenates analyzed by LC-MS. Barry 
and coworker discussed the legitimacy of LC-MS validation of Q-MSI based on three 
case studies336. Only if the MSI image shows a homogenous distribution, LC-MS data is 
comparable to Q-MSI data. Because our LC-MS data was obtained from assays that 
homogenize the whole liver tissue, as a consequence, we only compare the quantified 
MRM data of the liver parenchyma with the LC-MS data since the contribution of the 
parenchyma to homogenized tissue is by far the largest. Three different regions of 
interest were extracted from the liver parenchyma (n=3). We only report concentration 
ranges of the LC-MS data from the dog livers due to confidentiality of the drug 
candidates. LC-MS concentrations for compound A and B obtained in dog liver 1 were 
~150-220 µg/g and ~120-250 µg/g in dog liver 2. Drug concentrations of compound 
A found in dog liver 3 were above the upper limit of quantification (<ULOQ) and in dog 
liver 4 were ~1550-1650 µg/g. A comparison between quantitative LC-MS and 
quantitative DESI-MRM imaging demonstrated a difference in absolute concentrations 
of <3.5 times. Tissue heterogeneity, local information which is lost in LC-MS of tissue 
homogenates, influences the regional signal by the occurrence of tissue ion 
suppression. The ideal strategy to correct for this tissue ion suppression, is the use of 
an isotope-labelled analogue of the drug candidate. In addition, the contribution of the 
liver parenchyma to a tissue homogenate of the same liver sample is the largest but is 
not 100%. Therefore, the comparison of LC-MS of homogenates and Q-MSI of liver 
parenchyma could be inadequate. LC-MS and regional sampling, such as LESA137 or 
laser capture microdissection350, could provide more agreement between Q-MSI and 
LC-MS as the distribution in tissue is the starting point. 
 
5.4 Conclusions 
This work reports an optimized design for mimetic tissue model followed by an 
analytical assessment of its performance and a proof-of-concept drug application in Q-
MSI. Our optimized protocol fits into an ‘in-tissue’ approach and allows Q-MSI analysis 
of the sample tissue on the same glass slide. The large number of sections that can be 
obtained from one gelatin block can be used for large-scale drug studies. In addition to 
this mimetic tissue model, MRM imaging has been investigated in comparison to 
different MS modes. After evaluation of multiple MS modes, MRM imaging has 
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enhanced the analytical performance of Q-MSI. This is a consequence of the improved 
specificity obtained from MRM imaging and, therefore, can visualize more targeted 
analytes without the isobaric interference of background compounds. As a proof-of-
concept, Q-MSI drug levels were obtained from four different dog livers and compared 
with quantitative LC-MS. Although more animals are needed to confirm the obtained 
concentration levels, significant concentration differences were observed between 
tissue lesions, connective tissue and blood vessels, and liver parenchyma of the two 
animals (dog 1 and 2) that were dosed 65 mg/kg drug candidate B. The two animals 
(dog 3 and 4) that were dosed 65 and 15 mg/kg drug candidate A, respectively, did not 
show this accumulative behaviour of the drug candidate in the tissue lesion. The 
comparison with LC-MS data revealed a concentration difference of <3.5 times 
between quantitative LC-MS and quantitative MRM imaging for liver parenchyma. The 
analytical validation of Q-MSI is still challenging and needs to be compared with LC-
MS. Our developments contribute to a more robust Q-MSI workflow for drug imaging: 
an adapted mimetic tissue model for high throughput toxicological studies and a more 
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The research presented in this thesis focusses on innovative technological developments 
in quantitative ambient mass spectrometry imaging (MSI) for the pharmaceutical 
industry. There is a high demand for robust and validated imaging tools in the 
pharmaceutical pipeline. Over the last decade, MSI has established itself as one of those 
imaging tools that can distinguish between drug candidate and its metabolites. Early 
implementation of MSI in pre-clinical drug discovery and development (pharmacology) 
can prevent costly investments in potential drugs that proved not effective in the clinical 
phases. The impact of MSI on the pharmaceutical pipeline is indispensable which 
explains the broad interest from major pharmaceutical companies. Janssen 
Pharmaceutica (Janssen R&D in Beerse, Belgium) has expressed interest in applying MSI 
workflows in their laboratories alongside the existing LC-MS analyses. The collaborative 
research program between Janssen R&D and the Maastricht MultiModal Molecular 
Imaging (M4I) Institute was established in 2015. Janssen R&D not only provided funding 
but even more important supported this research program with drug candidates, tissue 
samples, and valuable expertise. Together with Janssen R&D, new research ideas were 
initiated, developed, and applied to their samples. Not surprisingly, the research 
presented in this thesis has led to the application of these new techniques and products 
that are directly translatable to their drug development process. The close collaboration 
did not only lead to sharing new techniques/products but also to knowledge transfer. 
In 2015, MSI was hardly known and pursued within Janssen R&D. Now five years later 
it has become an established technique, which is being used more and more in various 
parts of the drug discovery and development pipeline, and in a variety of therapeutic 
areas, like neuroscience, infectious diseases, oncology, etc. The research value of these 
techniques and products have been addressed in the individual thesis chapters. Here, 
we will briefly describe the commercial and economic impact of this research for Janssen 
R&D and other commercial collaborators. 
 
Spatial LC-MS analysis 
The collaboration between Janssen R&D and M4I started with a project to bridge LC-
MS with MSI and resulted in the development of the HR-LESA-µLC-IMS-MSE platform 
(Chapter 2). This platform was established together with our commercial partners from 
Advion (TriVersa NanoMate) and Waters Corporation (Acquity UPLC® and Synapt G2-
Si). The use of the TriVersa NanoMate as a spatial sampler and an LC autosampler in 
one is since our research publication sold by Advion as an additional TriVersa NanoMate 
module known as LESAplus. This allows already existing LC-MS methods to be upgraded 
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Q-MSI in pharmaceutical development 
The 3D printed mold for the preparation of a mimetic tissue model is a perfect example 
of how a collaborative environment leads to innovative ideas. After discussing a revised 
mimetic tissue model (Barry et al.), Darya Hadavi (a fellow M4I colleague) suggested to 
use a 3D printed mold for the preparation of a gelatin block. A brainstorm session 
resulted in a new design for a first prototype which was immediately tested in the M4I 
laboratory. After the prototype was optimized to the final version, Janssen requested a 
few extra copies to be used in their laboratory. This is the version that was used in the 





Figure 7.1 An image of the 3D printed mold that is implemented in an efficient Q-MSI workflow 
 
MRM based imaging 
At the M4I institute, the newest state-of-the-art mass spectrometers are available. This 
has been expressed by the introduction of M4I in the Waters Center of Innovation. 
Waters Corporation has been a key player on the market with innovative new MS 
instruments, amongst other fast high throughput triple quadrupole (QqQ) instruments. 
The purchase of the DESI source from Prosolia proved that their interest is becoming a 
major provider of ambient imaging tools. The close collaboration between Waters 
Corporation, M4I, and Janssen R&D resulted in the investigation of DESI-MRM imaging 
and the analytical comparison of this technique with other DESI-MSI instruments/modes 
as presented in Chapter 4 and 5. The setup of DESI-QqQ in the M4I laboratory is 
represented in Figure 7.2. The ability of performing dual polarity experiments on a QqQ 
instrument saves an enormous amount of time and money when two experiments can 
be merged into one. Shortening analysis time for known compounds in large scale drug 
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Figure 7.2 Desorption electrospray ionization source mounted onto a triple quadrupole mass spectrometer 
 
After the multiplatform presented in Chapter 5, we believe that MRM based imaging 
for the pharmaceutical industry should become the standard mode of operation due to 
its improved analytical performance. In line with this statement, we should refer to the 
MALDI-QqQ instrument, FlashquantTM, manufactured by Applied Biosystems in 2007 
which has been taken off the market shortly after its release. One could conclude that 
the academic and industrial interest in MRM imaging is not significant. In 2007, the MSI 
field was ‘only’ 10 years old and very much in a developmental stage in where new 
imaging ion sources and MS instruments were commercialized. The investigation of 
applied MSI became much later. We assume that in 2007 insignificant fundamental 
research showed the benefit of MRM imaging leading to not enough interest in an 
instrument suitable for standardized routine analysis. Nowadays, MSI is much more 
focused on its application and is in our opinion ready for sensitive and reliable 
pharmaceutical MRM imaging applications that will continue to add value from 
fundamental and methodological research.  
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7.1 General discussion 
Technological and instrumental developments in MSI have resulted in an analytical tool 
that provides indispensable qualitative data in the last two decades. Currently, MSI is 
finding its way into clinical, biomedical and pharmaceutical applications. Nevertheless, 
the MSI community still faces several challenges. Analysis speed needs to be increased 
to make MSI more suitable for high throughput routine analysis in a clinical and 
industrial setting. In line with the demand for routine analysis, the reproducibility and 
robustness of MSI workflows should be improved and standardized to meet validation 
criteria. Higher spatial resolution, mass resolving power and isomeric separation power 
could disclose a better understanding in biological processes. Identification of these 
new unknown imaged biomarkers is crucial as they could be markers of disease or a 
possible drug target. Due to limited sample cleanup abilities in MSI, only a fraction of 
the analytes observed in chromatographic techniques is detectable with MSI. Therefore, 
a more sensitive MSI approach could achieve higher compound coverage. Robust 
quantitative MSI (Q-MSI) workflows would reveal spatial absolute concentrations, which 
is on high demand in the pharmaceutical industry. All these MSI hurdles are not 
standalone and rely on each other.  
 
This thesis proposes technological improvements to overcome some of these challenges 
and starts to address the lack of sample cleanup and ion suppression in MSI. Enhanced 
analyte coverage is presented by the integration of LC with an ambient spatial sampling 
tool, LESA. Isomeric separation has been addressed by the integration of both LC and 
IMS. To improve selectivity and, as a result, sensitivity in MSI, MRM based ambient 
imaging is presented using DESI on a QqQ instrument. In addition, this novel targeted 
imaging approach is very applicable in a high throughput setting (< 30 min/image; due 
to the increased total detection time per precursor ion) and provides identification of 
known analytes. DESI-MRM imaging was subsequently further investigated for 
quantitative analysis. A mimetic tissue model is optimized by using a 3D-printed mold 
and applied in an MSI comparison which resulted in an MRM based Q-MSI workflow 
for pharmaceuticals. 
 
7.1.1 Analyte coverage 
Chapter 2 presented a novel fully automated platform that combines high resolution 
LESA with LC, IMS, and data independent acquisition (MSE) to identify detected species. 
The occurrence of ion suppression has been a real burden for the MSI community as 
the majority of the MSI tools only detects the ‘tip of the iceberg’. Our HR-LESA-µLC-
IMS-MSE platform removes interfering compounds from the sample prior to ionization. 
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This led to an enormous increase in detected compounds directly extracted from the 
tissue sample. In two different tissue brain samples, a substantial number of 
neuropeptides, 67 and 14, have been detected and identified, while the same sampling 
approach without LC separation only detected 5 and 4 of those neuropeptides. This 
work proved that our novel platform would be an ideal tool to investigate complex 
biological questions that require significantly higher analyte coverage. The proposed 
strategy uses fast MSI analysis that can guide towards the location of interest for our 
HR-LESA-µLC-IMS-MSE platform.  
 
Derivatization of analytes is a strategy to improve the ionization efficiency of poorly 
ionizing compounds. Chapter 3 presents the Girard’s reagent T (GT) derivatization of 
prostanoids to overcome poor ionization in negative ionization mode. GT provides a 
positive charge to the carbonyl group of the prostanoid. Demonstration of endogenous 
prostanoid analysis proved that the efficiency of derivatization is a way to ‘show more 
of the iceberg’ and improve analyte coverage of low-abundant molecules. 
 
7.1.2 Isobaric and isomeric separation 
The platform presented in Chapter 2 not only combines spatial sampling with 
chromatography but also uses traveling wave IMS (TWIMS) to separate isobars and 
removes interfering background ions from the MS spectra. The isobars in Chapter 2 
are from two different compounds that, due to different charge states, are overlapping 
in the mass spectrum and co-elute on the LC column. TWIMS is able to separate them 
due to different size-to-charge ratios of the isobars. Although not as significant as with 
LC, the removal of interfering background ions from the MS spectrum also slightly 
increases the analyte coverage of the platform. TWIMS and LC both have proven to 
separate both isobars and isomers. In theory, the HR-LESA-µLC-IMS-MSE platform could 
be applied in situations where isomeric separation is required. Our platform is a 
multidimensional platform that can sample tissues in the xyz-direction and integrates 
this with four more dimensions: chromatographic retention time, ion mobility arrival 
time, m/z ratio, compound identification by MSE.  
 
Isomeric separation by high resolution IMS is demonstrated in Chapter 3. A comparison 
between cIMS, TIMS and FAIMS showed that all high resolution IMS allows for isomeric 
separation of GT derivatized prostanoids. The comparison revealed advantages and 
limitations of linear and nonlinear IMS. Due the reduced pressure conditions, linear IMS 
provided the best sensitivity. Although all high resolution IMS allowed isomeric 
separation, not all isomers in our standard mixture were separated by all three IMS 
techniques. Only nonlinear FAIMS was able to separate all isomeric standards. That 
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there is a need for high resolution IMS combined with MSI, is shown by the increasing 
number of publications that integrate both techniques121, 122, 246, 352.   
 
This thesis presents several technological developments that can improve analyte 
coverage and isomeric separation necessary for the MSI field by the use of LC (minimize 
ion suppression) and IMS (removal of background ions). However, it should be 
mentioned that the integration of LC in an imaging experiment has practical limitations. 
The time necessary to analyze one liquid extraction is in the range of 10-30 minutes. 
This makes analysis of tissue surfaces a very time-consuming process. Since high 
throughput MSI analysis requires the experimental time for mapping tissue samples to 
be <30 min, research focusses on the integration of IMS instead of LC to improve 
isomeric separation power to MSI. There are several MS instruments manufactured with 
integrated IMS and their use with MSI ionization sources is easily established. Despite 
the practical limitation of LC and MSI integration, chromatographic separation prior to 
ionization remains the way to improve analyte coverage and reduce ion suppression.  
 
7.1.3 Selectivity and sensitivity 
A third option to improve separation and analyte coverage in MSI is to increase 
selectivity of the MS analysis. Chapter 4 presents a targeted imaging approach in which 
DESI is coupled to a QqQ instrument. The QqQ instrument operated in several MS/MS 
modes as introduced in paragraph 1.2.4. MRM imaging is compared to scanning modes 
and resulted in increased ion detection for selected precursor ions for lipids in rat brain 
tissue. Interfering background ions are eliminated from the MS analysis due to added 
specificity and selectivity for the targeted precursor-fragment ion transitions. Two drug 
candidates were analyzed in dog liver tissue with multiple MRM transitions from the 
same precursor and confirmed the spatial distribution of both compounds. A QqQ 
instrument is very suitable for dual polarity experiment because of rapidly switching ion 
optics. Dual polarity imaging experiments were executed detecting drug 
candidates/metabolites in positive ionization mode and bile acids in negative ionization 
mode. In addition, the QqQ instrument is a compact instrument and (relatively) not 
expensive to purchase which makes it very suitable in pharmaceutical industry.  
 
The potential of MRM imaging is further investigated in Chapter 5 where the 
performance of MRM is compared to Q-TOF instruments in MS scan, TWIMS and MSE 
operational modes. This multiplatform comparison investigates selectivity of MRM, IMS 
and MSE by DESI imaging of spiked tissue homogenate calibration lines in triplicate. 
Limits of detection extracted from these calibration lines prove that MRM is significantly 
more effective in removing background ions than TWIMS and, as a result, more 
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sensitive. As mentioned in this discussion, technological improvements could play are 
role to overcome multiple MSI hurdles. We believe that is the case for MRM imaging. 
The sensitivity gain is only one important aspect but could have a significantly positive 
effect on analysis speed, spatial resolution, reproducibility, and quantification. For 
instance, an imaging technique with higher sensitivity, like MRM imaging, can be used 
to analyze the same tissue section faster or at a smaller pixel size. In the latter case, the 
higher sensitivity is necessary because of the decreased number of molecules/ions per 
pixel. Higher sensitivity will allow detection of lower abundant species with better 
precision due to higher signal-to-noise ratios. This translates to more accurate 
quantification of targeted analytes in tissues. 
  
7.1.4 Quantification 
A large number of research and reviews have been published about quantification in 
MSI as this is one of the major challenges. Due to tissue variability, the application of 
calibration standards is an ongoing topic of discussion. Calibration standards are 
spotted on top of tissues and below tissue sections. In an ideal situation, these standards 
would be mixed with the tissue to best mimic the tissue environment and correct for 
extraction and ionization efficiencies. Therefore, we chose for the application of a 
mimetic tissue model. Chapter 5 demonstrates MRM imaging in an adapted Q-MSI 
workflow. First, the practical application of a mimetic tissue model is improved by using 
a 3D printed mold for the preparation of a gelatin block. This gelatin block is designed 
with 15 squared holes for the application of the tissue homogenate samples. With total 
dimension of 2x2 cm, the gelatin block is easily positioned beside the tissue sample on 
the glass slide. The depth of the holes is 8 mm which makes the block suitable for large 
scale Q-MSI analysis. Our adapted mimetic tissue model allows not only for an ‘in-tissue’ 
Q-MSI approach with the sample tissue and mimetic tissue model on the same glass 
slide but is also applicable to large drug studies.  
 
In our multiplatform comparison, the analytical performance of all instruments is 
determined for two drug candidates. Sensitivity, linearity, precision, and accuracy are 
calculated for all instruments in all modes. The combination of these validation 
parameters proved in significant favor of MRM imaging for two drug candidates. Now 
that the MSI community works towards standardization in its workflows, we believe 
that MRM imaging can lead to an accurate and reproducible quantitative analytical 
imaging tool. LC-MRM is currently the preferred tool for routine quantitative analysis in 
the pharmaceutical industry. Our quantitative MRM imaging work is presented as a first 
step towards a standardized industrial workflow. Bioanalytical methods in the 
pharmaceutical industry perform under standardization guidelines from authorities (i.e. 
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FDA or EMA). These guidelines are constructed for analytical methods that involve 
chromatography, such as LC-MRM, and MRM based Q-MSI strategies still have some 
steps to make. However, our work proved to significantly contribute to a better 
performance of the Q-MSI analysis. 
 
The use of an internal standard (IS), a stable isotope-labelled analogue of the drug 
candidate, is the ideal strategy to correct for ion suppression and variation throughout 
the analysis. However, the application of the IS with a mimetic tissue model has practical 
challenges, such as homogenously spraying the IS over an imperfectly cryosectioned 
tissue sample. In Chapter 5, we offer an alternative for spraying an internal standard 
on top or below the tissue sample. In drug discovery and development, an IS of the 
drug candidate is often not available. We present a workflow in which an endogenous 
cell membrane lipid is used for correction. Public software (Qupath) is used to perform 
a cell count analysis on the H&E image of the tissue sample and color these cells. This 
H&E image is overlaid with the MS images and overlapping pixels were extracted and 
quantified with the spiked tissue homogenates from the mimetic tissue model. Where 
legitimate, the absolute concentrations were compared to absolute concentrations 
obtained by LC-MRM. Our approach proved to be comparable to LC-MRM with 
concentration differences by a factor of <3.5. The measured concentration levels by Q-
MSI are in the range of µg/g tissue at 50 µm pixel size while LC-MRM often reaches 
limits of detection in the range of ng/g or even pg/g tissue. Laser capture 
microdissection (LCM) combined with LC-MRM is a strategy to achieve regional 
absolute quantification in tissue samples. This approach was investigated for 
quantitative drug imaging, however, we came across a few weaknesses. Dehydration 
of the cryosectioned tissue section is needed to prevent disruption in the LCM process. 
Dehydration is often performed by washing the tissue section in an organic solvent and, 
as a result, would delocalize and/or remove the drug compound. The second 
observation was that LCM-LC-MRM is a time-consuming approach for one tissue 
section. From a practical point of view, we believe that the feasibility of LCM-LC-MRM 
is low for large scale drug imaging studies. However, as suggested for HR-LESA-µLC-
IMS-MSE, an MSI guided application of quantitative LCM-LC-MRM can give insight in 
the pharmacological process. 
 
In summary, this thesis highlights the importance of enhanced separation in MSI using 
ambient tissue sampling tools and offers new technologies to address the main 
challenges associated with Q-MSI: i) Integration of spatial sampling with LC and IMS, ii) 
High resolution IMS, and iii) MRM imaging. These new technologies lead to increased 
number of analytes detected, better isomeric separation power, higher selectivity and 
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sensitivity, and ultimately results in a robust and reproducible MRM based quantitative 
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7.2 Summary 
In the pharmaceutical industry the development and application of good separation 
methods is important to study the effect of a potential drug. These techniques allow us 
to expand our knowledge of the disease and the systemic reaction of a drug and 
corresponding metabolites. The effect of a potential drug is studied by executing 
pharmacodynamics and pharmacokinetic studies (pharmacology). Pharmacology 
determines what a drug in development does to the human body (pharmacodynamics) 
and what the human body does to the drug (pharmacokinetics). After administration, 
the aim of the drug is to metabolize and being transported to the site of disease. The 
desired effect is that the drug binds to the biological receptors following by the 
inhibition of the processes that cause the disease. The binding to these biological 
receptors has to occur for a certain amount of time at a high enough drug 
concentration. To monitor this process, analytical techniques have to meet certain 
criteria: i) being able to measure absolute concentrations, ii) the location of the potential 
drug has to be measurable, and iii) both the potential drug and related metabolites 
have to be separately measured in those pharmacological studies. This is currently done 
by whole body autoradiography (WBA), liquid chromatography mass spectrometry (LC-
MS), and mass spectrometry imaging (MSI).  
 
In the past two decades, MSI has developed to a technique with enormous additional 
value to the pharmaceutical industry because it is able to separate drug from 
metabolites and besides this able to measure both their location in tissue samples. MSI 
meets two of the three technical requirements for the pharmaceutical industry. The 
measurement of absolute concentrations is a challenge for the MSI community. A huge 
burden is the phenomenon ion suppression. This is caused by the presence (besides the 
drug and metabolites) of other surrounding sample molecules that interfere in the 
ionization process of the drug and metabolites, which leads to a less optimal detection 
of the drug and metabolites. This thesis presents a few novel technological 
developments in MSI that can contribute to improved quantitative MSI analyses of drugs 
and metabolites. 
 
Chapter 2 presents a platform that combines LC-MS with MSI, called high resolution 
liquid extraction surface analysis micro liquid chromatography ion mobility separation 
data independent acquisition (HR-LESA-µLC-IMS-MSE). This platform shows the 
strength of complementary separation. First, HR-LESA sampling is performed with a 
spatial resolution of 400 µm. Then, after a short online washing step to remove salts, a 
chromatographic separation (µLC) is executed followed by an ion mobility spectrometry 
(IMS) analysis and data independent acquisition (MSE). Two different neuropeptide 
applications are exhibited: the analysis of rat pituitary gland and the analysis of 
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knockout and control mice brain for an Alzheimer’s disease model. The analytical 
platform is not only highly reproducible but more importantly also allows isobaric 
separation by µLC and IMS and a significant increased number of detected 
neuropeptides due to the µLC sample separation prior to ionization.  
 
The use of high resolution IMS is further investigated in Chapter 3. Linear cyclic IMS 
(cIMS), linear trapped IMS (TIMS), and nonlinear field asymmetric waveform IMS (FAIMS) 
are compared for the isomeric separation of ten prostanoids, including the biologically 
relevant prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2). These prostanoids are 
derivatized with Girard’s reagent T to improve their ionization efficiency. A significant 
difference is observed between linear and nonlinear IMS in the IMS comparison. Linear 
IMS shows the highest intensity and nonlinear IMS the best resolution due to its 
orthogonality to MS. Another huge difference is that cIMS and TIMS occur in vacuum 
while FAIMS is executed at atmospheric pressure. This causes lower ion transmission in 
FAIMS due to collisions with surrounding molecules. That a high total transmission of 
ions is crucial for a technique that separates after ionization, is shown by the analysis 
of endogenous prostanoids in mini pig intestine tissue. The limited ion transmission in 
FAIMS causes, in combination with ion suppression, for a low number of detected ions. 
Linear IMS shows a higher intensity, however, no separation of the biologically relevant 
PGD2 and PGE2 is observed. Our research shows the potential of high resolution IMS as 
a tool for isomeric separation of prostanoids.  
 
Chapter 4 introduces a targeted imaging strategy, named desorption electrospray 
ionization (DESI) multiple reaction monitoring (MRM) imaging. This work reports a lipid 
application and a drug and metabolite application which shows the benefit of MRM 
imaging. MRM imaging has the following advantages: i) increased specificity and 
selectivity due to the different MRM transitions of isobaric precursor ions, ii) by multiple 
MRM transitions from the same precursor ion, local distribution from the analyte can 
be confirmed, and iii) fast optical switching possibility in a triple quadrupole mass 
spectrometer (QqQ) allows positive and negative ions to be detected in one experiment. 
The measurement in tandem mass spectrometry (MS/MS) scan imaging mode is 
compared with by MRM imaging of the same precursor ions. Because the first and third 
quadrupole operate in selection mode rather than scanning mode in the same time 
period, sensitivity has significantly increased for these precursor ions.  
 
The increased sensitivity of DESI-MRM is further investigated as technique for 
quantitative MSI (Q-MSI) in Chapter 5. Quantification is executed by use of an optimized 
mimetic tissue model. A gelatin block is prepared from a new designed 3D printed mold 
with 15 pilars to which calibration lines from tissue homogenates are added. MSI 
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experiments are performed with different mass spectrometers in different modes: i) 
Xevo G2 Q-TOF in MS scan mode, ii) Synapt G2-Si Q-TOF in MS scan, IMS-MS scan, and 
IMS-MSE scan modes, and iii) Xevo TQS micro QqQ in MS scan and MRM modes. The 
limit of detection, linearity, precision, and accuracy are determined for each of the MS 
modes and compared with each other. Overall, the analytical performance of MRM 
imaging proved the best and, therefore, DESI-MRM is used for the quantitative analyses 
of four dog livers. The comparison of absolute concentrations from Q-MSI with LC-
MRM is debatable because regional differences get lost in the homogenization of tissue 
samples in the LC-MRM analysis. For this reason we only compare regional liver 
parenchyma (due to its substantial contribution to liver homogenates) Q-MSI 
concentrations with the LC-MRM data: the absolute concentrations differ by a factor 
of <3.5.  
 
The technological developments presented in this thesis contribute to an increased 
number of detected analytes, better isobaric and isomeric separation, higher selectivity 
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7.3 Samenvatting 
In de farmaceutische industrie is het van belang dat goede scheidingsmethode 
ontwikkeld en toegepast worden om het effect van een potentieel medicijn in kaart te 
brengen. Deze technieken staan ons toe om onze kennis van het ziektebeeld en de 
systemische reactie van een medicijn en bijbehorende metabolieten te vergroten. Het 
effect van een potentieel medicijn wordt gevolgd door het uitvoeren van 
farmacodynamische en farmacokinetische studies (farmacologie). In farmacologie 
wordt onderzocht wat een medicijn in ontwikkeling doet met het menselijk lichaam 
(farmacodynamiek) en wat het menselijk lichaam doet met dit potentiele medicijn 
(farmacokinetiek). Het doel van het medicijn is om na toediening gemetaboliseerd te 
worden en verplaatst naar de plaats van de ziekte. Hier is het gewenste effect dat het 
medicijn dan bindt aan biologische receptoren die vervolgens de processen die 
betrokken zijn bij de ziekte tegen werken. De binding aan de biologische receptoren 
moet voor een bepaalde tijd met een medicijnconcentratie die hoog genoeg is. Om dit 
goed te bestuderen moet de analytische techniek(en) aan een aantal criteria voldoen: i) 
de absolute concentratie moet gemeten kunnen worden, ii) de locatie van het 
potentiele medicijn moet gemeten kunnen worden, en iii) zowel het potentiele medicijn 
als gerelateerde metabolieten moeten in deze farmacologische studies gescheiden 
kunnen worden. Dit wordt momenteel gemeten door autoradiografie van het hele 
lichaam (WBA), vloeistofchromatografie-massaspectrometrie (LC-MS) en 
massaspectrometrie imaging (MSI).  
 
MSI heeft zich in de afgelopen twee decennia ontwikkeld tot een techniek met een 
enorme toegevoegde waarde voor de farmaceutische industrie omdat het in staat is om 
medicijnen van metabolieten te scheiden en daarnaast in staat is om de locatie van deze 
moleculen in weefsels te meten. Hiermee is MSI in staat om aan twee van de drie 
vereisten voor de farmaceutische industrie te voldoen. Het meten van absolute 
concentraties met MSI is een uitdaging voor de MSI-gemeenschap. De grootste drempel 
hierin is het fenomeen ion suppressie. Dit wordt veroorzaakt doordat (naast het 
aanwezige medicijn en metabolieten) het monster ook bestaat uit andere moleculen 
die het ionisatieproces van het medicijn en zijn metabolieten kunnen verstoren 
waardoor deze minder goed ioniseren en daardoor deze minder goed te detecteren 
zijn. Om het effect van ion suppressie te minimaliseren presenteert dit proefschrift een 
aantal technologische ontwikkelingen in MSI die kunnen bijdragen aan een verbeterde 
kwantitatieve MSI-analyse van medicijnen en metabolieten. 
 
Hoofdstuk 2 presenteert een platform dat LC-MS combineert met MSI, genaamd hoge 
resolutie vloeistof extractie oppervlakte analyse micro vloeistofchromatografie 
ionmobiliteitsspectrometrie data onafhankelijke acquisitie (HR-LESA-µLC-IMS-MSE). Dit 
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platform laat de kracht van complementaire scheiding zien. Allereerst wordt 
aangetoond dat de monsterneming met HR-LESA uitgevoerd wordt met een lokale 
resolutie van 400 µm. Vervolgens wordt, na een korte online wasstap om zouten te 
verwijderen, een chromatografische scheiding (µLC) uitgevoerd welke opgevolgd wordt 
met een ionmobitiliteitsspectrometrie (IMS) analyse en een data onafhankelijke 
acquisitie (MSE). Twee verschillende neuropeptide applicaties worden getoond: de 
analyse van de hypofyse van ratten en de analyse van zieke en controle muishersenen 
uit een model waarin de ziekte van Alzheimer wordt onderzocht. Het analytische 
platform is niet alleen hoge reproduceerbaarheid maar vooral ook isobare scheiding 
door middel van µLC en IMS en een significante toename van het aantal gedetecteerde 
neuropeptiden door monsterscheiding voor de ionisatiestap door µLC.  
 
Het gebruik van hoge resolutie IMS wordt verder bestudeerd in Hoofdstuk 3. Hierin 
worden lineaire cyclische IMS (cIMS), lineaire gevangen IMS (TIMS) en niet-lineaire veld 
asymmetrische golfvorm IMS (FAIMS) met elkaar vergeleken voor de isomere scheiding 
van een tiental prostanoiden, waaronder biologische relevante prostaglandine D2 
(PGD2) en prostaglandine E2 (PGE2). Deze prostanoiden worden eerst gederivatiseerd 
met Girard’s reagens T om de ionisatie efficiëntie te vergroten. In de IMS-vergelijking 
wordt een significant verschil tussen lineaire en niet-lineaire IMS waargenomen. Lineaire 
IMS laat de hoogste intensiteit zien en niet-lineaire IMS de beste resolutie door zijn 
orthogonaliteit ten opzichte van MS. Een ander groot verschil is dat cIMS en TIMS in 
vacuüm plaatsvindt terwijl FAIMS bij atmosferisch druk uitgevoerd wordt. Dit zorgt 
ervoor dat de ion transmissie lager is in FAIMS door botsing met omgevingsmoleculen. 
Dat de totale transmissie van ionen cruciaal is in een techniek die na de ionisatiestap 
scheidt, blijkt uit de analyse van endogene prostanoiden in minivarken darmweefsel. 
De beperkte ion transmissie in FAIMS zorgt er, in combinatie met ion suppressie, voor 
dat een minimaal aantal ionen gedetecteerd wordt. Lineaire IMS laat een hogere 
intensiteit zijn maar er is daarentegen geen scheiding geobserveerd voor de biologische 
relevante isomeren PGD2 en PGE2. Ons onderzoek laat zien dat hoge resolutie IMS een 
techniek kan zijn voor isomere scheiding van prostanoiden. 
 
Hoofdstuk 4 introduceert een doelgerichte imaging analyse strategie, genaamd 
desorptie electrospray isonisatie (DESI) meerdere reactie monitoring (MRM) imaging. Dit 
werk rapporteert een lipiden en medicijn en zijn metaboliet applicatie waarin het 
voordeel van MRM imaging wordt gepresenteerd. MRM imaging heeft de volgende 
voordelen: i) vergrootte specificiteit en selectiviteit door de verschillende MRM 
overgangen van isobare moederionen, ii) met meerdere MRM overgangen van 
hetzelfde moederion kan de lokale distributie van dit analiet bevestigd worden, en iii) 
door de snelle optische omschakkelingsmogelijkheid van een drievoudige quadrupool 
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massaspectrometer (QqQ) kunnen positieve en negatieve ionen in een experiment 
gedetecteerd worden. Het meten in een tandem massaspectrometrie (MS/MS) scan 
imaging modes wordt vergeleken met MRM imaging voor dezelfde moederionen. 
Doordat de eerste en derde quadrupool nu in selectie modes opereert in plaats van 
scanning modes in hetzelfde tijdsbereik, is de gevoeligheid significant toegenomen voor 
deze moederionen. 
 
Deze gevoeligheidstoename van DESI-MRM wordt verder onderzocht als techniek voor 
kwantitatieve MSI (Q-MSI) in Hoofdstuk 5. Kwantificatie wordt uitgevoerd door middel 
van een geoptimaliseerd nabootsend weefselmodel. Hierin wordt een gelatineblok 
gemaakt uit een nieuw ontworpen 3D geprinte gietvorm met 15 pilaren waarin 
vervolgens kalibratielijnen van weefselhomogenaten wordt toegevoegd. MSI-
experimenten worden uitgevoerd met verschillende massaspectrometers in 
verschillende modes: i) Xevo G2 Q-TOF in MS scan mode, ii) Synapt G2-Si Q-TOF in MS 
scan, IMS-MS scan en IMS-MSE scan modes, en iii) Xevo TQS micro QqQ in MS scan en 
MRM modes. Het detectielimiet, lineairiteit, precisie en accuraatheid wordt bepaald 
voor elk van de MS modes en vergeleken met elkaar. Over het algemeen is de 
analytische prestatie van MRM imaging het best en daarom is er voor de kwantitatieve 
analyse van vier hondenlevers gekozen voor DESI-MRM. De vergelijking van absolute 
concentraties uit Q-MSI met kwantitatieve LC-MRM experimenten is discutabel 
aangezien de LC-MRM analyse altijd op een gehomogeniseerde versie van het weefsel 
is waarin regionale verschillen verloren gaan. Om deze reden vergelijken we alleen 
regionale lever parenchym (door de substantiële bijdrage van lever parenchym aan de 
lever homogenaten) Q-MSI concentraties met de LC-MRM data: de absolute 
concentraties wijken een factor < 3,5 af.  
 
De technologische ontwikkelingen die dit proefschrift presenteert dragen bij aan een 
toename in het aantal te detecteren analieten, betere isobare en isomere scheiding, 
hogere selectiviteit en gevoeligheid en uiteindelijk in een betere kwantitatieve 
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8.2 List of abbreviations 
 
AC  Alternating current 
ACN  Acetonitrile 
ADC  Analog-to-digital converters 
ADME  Absorption, distribution, metabolism, and excretion 
CE  Collision energy 
CID  Collision-induced dissociation 
cIMS  Cyclic ion mobility spectrometry 
COX  Cyclooxygenase 
CRM  Charge residue model 
CV  Compensation voltage 
CZE  Capillary zone electrophoresis 
Da  Dalton 
DC  Direct current 
DDA  Data-dependent acquisition 
DESI  Desorption electrospray ionization 
DTIMS  Drift-time ion mobility spectrometry 
EMA  European Medicine Agency 
ESI  Electrospray ionization 
EtOH  Ethanol 
FA   Formic acid 
FAIMS  Field asymmetric ion mobility spectrometry 
FT-ICR  Fourier Transform Ion Cyclotron Resonance mass analyzer 
GC  Gas chromatography 
GT  Girard's reagent T 
H&E  Hematoxylin and eosin 
H2O  Water 
HPLC  High performance liquid chromatrography 
HR  High resolution 
IEM  Ion evaporation model 
IMS  Ion mobility spectrometry 
IS  Internal standard 
IV  Intravenous 
LA/LCSA  Laser ablation liquid capture surface analysis 
LAESI  Laser ablation electrospray ionization 
LC  Liquid chromatography 
LCM  Laser capture microdissection 
LESA  Liquid extraction surface analysis 
LeuEnk  Leucine enkephalin 
LIT  Linear ion trap mass analyzer 
LLOQ  Lower limit of quantification 
LMJ/SSP  Liquid microjunction surface sampling probe 
LOD  Limit of detection 
m/z  mass-to-charge ratio 
MALDI  Matrix-assisted laser desorption ionization 
MeOH   Methanol 
MRM  Multiple reaction monitoring 
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MS  Mass spectrometry 
MS/MS  Tandem mass spectrometry 
MSE/DIA  Data-independent acquisition 
MSI   Mass spectrometry imaging 
nano-DESI Nanospray desorption electrospray ionization 
NL  Neutral loss scan 
NMR  Nuclear magnetic resonance 
PC  Phosphatidylcholine 
PD  Pharmacodynamics 
PE  Phosphatidylethanolamine 
PGD2  Prostaglandin D2 
PGE2  Prostaglandin E2 
PGF2a  Prostaglandin F2a 
PGHS  Prostaglandin G/H synthases 
PGI2  Prostaglandin I2 
PK  Pharmacokinetics 
POMC  Pro-opiomelanocortin 
PREC  Precursor ion scan 
PROD  Product ion scan 
PS  Phosphatidylserine 
PTM  Post-translational modifications 
QC  Quality control 
Q-MSI  Quantitative mass spectrometry imaging 
QqQ  Triple quadrupole mass spectrometer 
Q-TOF  Quadrupole time-of-flight mass spectrometer 
Q-WBA  Quantitative whole body autoradiography 
RF  Radio frequency 
ROI  Region of interest 
RSD  Relative standard deviation 
SD  Standard deviation 
SIM  Selected ion monitoring 
SIMS  Secondary ion mass spectrometry 
SM  Sphingomyelin 
SRM  Selected reaction monitoring 
SWATH  Sequential windowed acquisition of all theoretical fragment ion mass spectra 
TEC  Tissue extinction coefficient 
TIMS  Trapped ion mobility spectrometry 
TOF  Time-of-flight mass analyzer 
TQ  Tandem quadrupole mass spectrometer 
TWIMS  Travelling wave ion mobility spectrometry 
TxA2  Thromboxane A2 
U(H)PLC  Ultra (high) performance liquid chromatography 
ULOQ  Upper limit of quantification 
WBA  Whole body autoradiography 
XIC  Extracted ion chromatogram  
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